

CITATION REPORT

List of articles citing

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

DOI: 10.1182/blood-2009-03-209262
Blood, 2009, 114, 937-51.

Source: <https://exaly.com/paper-pdf/47070435/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2201	Acute lymphoblastic leukemia. 127-145		
2200	Advances in prognostication and treatment of pediatric acute leukemia. 345-356		
2199	[Mutations in TET2 in myeloid cancers]. 2009 , 25, 785-8		3
2198	Role of nucleophosmin in acute myeloid leukemia. 2009 , 9, 1283-94		29
2197	How I treat hypereosinophilic syndromes. <i>Blood</i> , 2009 , 114, 3736-41	2.2	35
2196	The changing classification of myelodysplastic syndromes: what's in a name?. 2009 , 645-55		14
2195	Epigenomics, microRNAs and leukemias. 2009 , 1, 219-22		
2194	TET proteins in malignant hematopoiesis. 2009 , 8, 4044-8		44
2193	[Diagnostics and therapy of acute myeloid leukemia]. 2009 , 134, 1935-41		0
2192	Reply to J. Thiele et al. 2009 , 27, e222-e223		7
2191	Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 2010 , 85, 14-7		30
2190	The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. 2010 , 28, 13-9		34
2189	5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. 2009 , 28, 3429-41		66
2188	Myelodysplastic syndromes. 2009 , 361, 1872-85		527
2187	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. 2009 , 2009, 704928		12
2186	Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. 2009 , 9, 1295-304		7
2185	Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. 2009 , 6, 627-37		102

2184	Cytogenetics and molecular genetics of acute lymphoblastic leukemia. 2009 , 23, 991-1010, v		88
2183	Thrombocytosis. 2009 , 159-67		34
2182	Treatment of MDS: something old, something new, something borrowed. 2009 , 656-63		4
2181	Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. 2009 , 94, 1041-3		5
2180	Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. <i>Blood</i> , 2009 , 114, 1063-72	2.2	125
2179	Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. 2010 , 95, 1473-80		57
2178	Current world literature. 2010 , 22, 664-8		
2177	Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. 2010 , 17, 125-32		67
2176	High cytogenetic or molecular genetic risk acute myeloid leukemia. 2010 , 2010, 474-80		11
2175	Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. <i>Blood</i> , 2010 , 115, 1976-84	2.2	269
2174	Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?. <i>Blood</i> , 2010 , 115, 1490-9	2.2	48
2173	WHO classification of myeloid neoplasms and leukemia. <i>Blood</i> , 2010 , 115, 748-9; author reply 749-50	2.2	16
2172	Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. <i>Blood</i> , 2010 , 115, 4350-5	2.2	33
2171	Validation of cytogenetic-based risk stratification in primary myelofibrosis. <i>Blood</i> , 2010 , 115, 2719-20	2.2	6
2170	Proposal for a revised classification of systemic mastocytosis. <i>Blood</i> , 2010 , 115, 2720-1	2.2	15
2169	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , 2010 , 116, 4422-9	2.2	280
2168	Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). <i>Blood</i> , 2010 , 116, 2742-51	2.2	84
2167	Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease. <i>Blood</i> , 2010 , 116, 6003-13	2.2	47

2166	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. <i>Blood</i> , 2010 , 116, 2420-8	2.2	62
2165	Combined simultaneous analysis of morphology and fluorescence in situ hybridization as a novel sensitive method for detecting small populations of malignant cells in patients with a high risk of cancer, premalignant lesions, and minimal residual disease. 2010 , 46, 1186-1189		
2164	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
2163	Demethylating Agents in the Treatment of Cancer. 2010 , 3, 2022-2044		41
2162	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. <i>Blood</i> , 2010 , 116, 1132-5	2.2	105
2161	Plasmablastic crisis of Philadelphia chromosome-positive chronic myeloid leukemia. 2010 , 89, 641-2		2
2160	[Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts]. 2010 , 31, 29-41		1
2159	[Myelodysplastic syndromes]. 2010 , 51, 169-82; quiz 183-4		
2158	Blastic plasmacytoid dendritic cell neoplasm presenting as a subcutaneous mass in an 8-year-old boy. 2010 , 40 Suppl 1, S40-2		8
2157	Genetic alterations in children and adolescents with acute myeloid leukaemia. 2010 , 12, 590-6		3
2156	Myelodysplastic syndromes: an update on molecular pathology. 2010 , 12, 652-61		15
2155	Myelodysplastic syndrome: classification and prognostic systems. 2010 , 4, 25-33		5
2154	Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. 2010 , 91, 174-9		79
2153	Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia. 2010 , 91, 557-68		24
2152	Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission. 2010 , 92, 398-400		16
2151	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. 2010 , 10, 401		125
2150	Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study. 2010 , 10, 516		28
2149	Targeted therapy of chronic myeloid leukemia. 2010 , 80, 584-91		23

2148	A novel t(5;11)(q31;p15) involving the NUP98 gene on 11p15 is associated with a loss of the EGR1 gene on 5q31 in a patient with acute myeloid leukemia. 2010 , 199, 9-14	5
2147	The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. 2010 , 184, 16-20	153
2146	Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. 2010 , 184, 50-7	63
2145	Incidence and susceptibility to therapy-related myeloid neoplasms. 2010 , 184, 39-45	67
2144	A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis. 2010 , 38, 685-95	16
2143	Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. 2010 , 84, 191-200	21
2142	Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders. 2010 , 32, 559-71	23
2141	The role of chromosome 21 in hematology and oncology. 2010 , 49, 497-508	23
2140	Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. 2010 , 116, 4549-63	73
2139	Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome. 2010 , 28, 202-8	8
2138	Nuclear inositide signaling in myelodysplastic syndromes. 2010 , 109, 1065-71	22
2137	Genetic polymorphisms in cytochrome P450s, GSTs, NATs, alcohol consumption and risk of non-Hodgkin lymphoma. 2010 , 85, 213-5	2
2136	ASH 2009 meeting report—Top 10 clinically oriented abstracts in myeloproliferative neoplasms. 2010 , 85, NA-NA	
2135	ASH 2009 meeting report—Top 10 clinically-oriented abstracts in hematopoietic stem cell transplantation. 2010 , 85, NA-NA	
2134	ASH 2009 meeting report—Top 10 clinically oriented abstracts in myelodysplastic syndromes. 2010 , 85, NA-NA	
2133	ASH 2009 meeting report—Top 10 clinically oriented abstracts in coagulation medicine and platelet disorders. 2010 , 85, NA-NA	
2132	ASH 2009 meeting report—Top 10 clinically oriented abstracts in sickle cell disease. 2010 , 85, NA-NA	
2131	ASH 2009 meeting report—Top 10 clinically oriented abstracts in multiple myeloma. 2010 , 85, NA-NA	

2130	ASH 2009 meeting report Top 10 clinically oriented abstracts in chronic lymphocytic leukemia. 2010 , 85, NA-NA	
2129	Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results. 2010 , 85, 687-90	7
2128	Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. 2010 , 34, 1308-13	25
2127	From FAB to 2008 WHO classification: the wide heterogeneity of refractory anemia subtype among different countries. 2010 , 34, 967-8	1
2126	Detangling fibrosis assessment in MPNs. 2010 , 34, 854-5	0
2125	Mixed myelodysplastic syndrome associated with beta-thalassemia intermedia. 2010 , 34, e221-3	2
2124	Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. 2010 , 34, 1410-6	43
2123	Post-essential thrombocythemia myelofibrosis and chronic myelomonocytic leukemia can co-exist with complex cytogenetic abnormalities. 2010 , 34, e308-10	0
2122	Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. 2010 , 24, 83-90	10
2121	Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. 2010 , 3, 23	27
2120	Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. 2010 , 10, 90-8	24
2119	Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. 2010 , 118, 353-9	10
2118	Current therapeutic approaches for patients with myelodysplastic syndromes. 2010 , 150, 131-43	23
2117	A recombinant trispesific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. 2010 , 150, 574-86	102
2116	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. 2010 , 151, 365-75	175
2115	Mast cell homeostasis and the JAK-STAT pathway. 2010 , 11, 599-608	62
2114	Myelodysplastic syndromes: lost between two states?. 2010 , 24, 1-5	33
2113	Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. 2010 , 24, 1539-41	6

2112	LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. 2010 , 24, 1713-8	156
2111	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. 2010 , 24, 1128-38	435
2110	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. 2010 , 24, 1146-51	160
2109	Abstracts of the XXIII International Symposium on Technological Innovations in Laboratory Hematology. May 10-12, 2010. Brighton, United Kingdom. 2010 , 32 Suppl 1, 1-175	7
2108	Nanocolonies and diagnostics of oncological diseases associated with chromosomal translocations. 2010 , 75, 1667-91	2
2107	Basal serum tryptase as risk assessment for severe Hymenoptera sting reactions in elderly. 2010 , 65, 919-23	47
2106	Mutational status of myeloproliferative neoplasms. 2010 , 20, 61-76	12
2105	An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. 2010 , 3, 1-13	19
2104	A 73-year-old-man with fever and weight loss. 2010 , 339, 164-8	
2103	Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic. 2010 , 57, 578-89	5
2102	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. 307-328	
2101	Cytogénétique des syndromes myélodysplasiques et apport des techniques pangénomiques. 2010 , 16, 8-11	
2100	Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor. 2010 , 45, 177-82	5
2099	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 2010 , 28, 5257-64	155
2098	Reply to F. Damm et al. 2010 , 28, e388-e389	1
2097	Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. 2010 , 28, 3872-9	59
2096	Enhanced platelet adhesion in essential thrombocythemia after in vitro activation. 2010 , 27, 82-90	
2095	Mastocytosis and Mast Cells. 2010 ,	

2094	Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. 2010 , 51, 783-8	15
2093	Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. 2010 , 10, 1663-72	29
2092	Assessing new therapies and their overall impact in myelofibrosis. 2010 , 2010, 115-21	13
2091	Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. 2010 , 28, 578-85	109
2090	Is the association of "cup-like" nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful?. 2010 , 134, 648-52	15
2089	IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. 2010 , 24, 2120-2	31
2088	Old-fashioned genetic screens give new insights to DNA replication. 2010 , 9, 4610-1	
2087	Toxicity and lifespan extension: complex outcomes of histone overexpression in budding yeast. 2010 , 9, 4611-2	1
2086	Establishment of sister chromatid cohesion: the role of the clamp loaders. 2010 , 9, 4615	2
2085	Nucleolar structure: it's all in a tangle. 2010 , 9, 4609-10	1
2084	Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms. 2010 , 9, 1051-6	11
2083	RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease. 2010 , 9, 4607	9
2082	Prognosis of myelodysplastic syndromes. 2010 , 2010, 330-7	19
2081	New prognostic markers in acute myeloid leukemia: perspective from the clinic. 2010 , 2010, 47-55	82
2080	miR-31 in cancer: location matters. 2010 , 9, 4608-9	9
2079	A combination of 1 α ,25-dihydroxyvitamin D ₃ , a plant-derived antioxidant and an inhibitor of the Cot1/Tlp2 oncogene as molecularly targeted weapons in the hematologist's battle against acute myeloid leukemias. 2010 , 9, 4612-3	
2078	Cdc25 phosphatases: differential regulation by ubiquitin-mediated proteolysis. 2010 , 9, 4613-4	8
2077	Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. 2010 , 36, 917-24	45

2076	The molecular pathogenesis of myelodysplastic syndromes. 2010 , 10, 309-19		32
2075	[Current treatment options for myelodysplastic syndromes]. 2010 , 135, 1863-9		
2074	[Mechanisms of leucemogenesis]. 2010 , 97, 1381-8		0
2073	The role of 9-O-acetylated ganglioside D3 (CD60) and α 4 β 1 (CD49d) expression in predicting the survival of patients with Sezary syndrome. 2010 , 95, 1905-12		12
2072	High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. 2010 , 28, 2101-7		189
2071	Cancer: Chromosomal Abnormalities. 2010 ,		1
2070	Myelodysplastic syndromes--many new drugs, little therapeutic progress. 2010 , 85, 1042-5		11
2069	The genetic basis of myelodysplastic syndromes. 2010 , 24, 295-315		25
2068	Prognostic classification and risk assessment in myelodysplastic syndromes. 2010 , 24, 459-68		34
2067	Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. 2010 , 85, 158-64		118
2066	Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. 2010 , 51, 576-82		8
2065	Practical approach to the patient with hypereosinophilia. 2010 , 126, 39-44		185
2064	A case of acute myeloid leukemia initially treated as chronic lymphocytic leukemia: what do we know about t(4;12)(q12;p13)? 2010 , 203, 348-51		4
2063	Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. <i>Blood</i> , 2010 , 115, 2003-7	2.2	141
2062	Myelodysplastic syndromes: a practical approach to diagnosis and treatment. 2010 , 77, 37-44		28
2061	Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. 2010 , 51, 2250-7		12
2060	Acute leukemia presenting with blasts first found in the cerebrospinal fluid but not in the peripheral blood. 2010 , 17, 1252-5		6
2059	Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. 2010 , 46, 1892-9		17

2058 Myelodysplastic syndromes: from neglect to prominence. **2010**, 16, S28-9

2057	Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. 2010 , 16, 555-9		39
2056	Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. 2010 , 16, 1018-24		12
2055	NF- κ B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. 2010 , 14, 1157-76		38
2054	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. 2010 , 11, 543-52		43 ²
2053	Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing. 2010 , 12, 278-82		16
2052	Innate immune signaling in the myelodysplastic syndromes. 2010 , 24, 343-59		34
2051	The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. <i>Blood</i> , 2010 , 116, 2315-23	2.2	73
2050	Refractory cytopenias with unilineage dysplasia: a retrospective analysis of refractory neutropenia and refractory thrombocytopenia. 2010 , 51, 1923-6		8
2049	Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. 2010 , 16, 3825-31		28
2048	Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). <i>Blood</i> , 2010 , 116, 3735-42	2.2	127
2047	Advances in understanding benzene health effects and susceptibility. 2010 , 31, 133-48 2 p following 148		219
2046	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. 2010 , 51, 995-1006		14
2045	Quantification of PDGFRA alternative transcripts improves the screening for X-PDGFRA fusions by reverse transcriptase-polymerase chain reaction. 2010 , 51, 1720-6		
2044	The renaissance of interferon therapy for the treatment of myeloid malignancies. <i>Blood</i> , 2011 , 117, 4706-15		153
2043	DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 2011 , 29, 392-7		677
2042	Relationship between clotting activity and phosphatidylserine expression on erythrocyte membranes in polycythemia vera patients with the JAK2 V617F mutation. 2011 , 117, 231-5		4
2041	Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. <i>Blood</i> , 2011 , 117, 2700-7	2.2	86

2040	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2011 , 118, 6239-46	2.2	365
2039	How I treat myelofibrosis. <i>Blood</i> , 2011 , 117, 3494-504	2.2	105
2038	Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. 2011 , 29, 1356-63		402
2037	Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. 2011 , 13, 461-6		16
2036	Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. 2011 , 13, 558-64		14
2035	Classificaçã da Organizaçã Mundial da Saãde para os tumores dos tecidos hematopoïtico e linfoide, 4a ediçã, 2008 - principais modificaçães introduzidas em relaçã ã3a ediçã, 2001. 2011 , 57, 66-73		3
2034	Myelodysplastic syndromes. 2011 , 31, 763-84		6
2033	Unraveling the molecular pathophysiology of myelodysplastic syndromes. 2011 , 29, 504-15		241
2032	Low dose cytarabine monotherapy for acute myeloid leukaemia. 2011 ,		
2031	World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 [major changes from the 3rd edition, 2001. 2011 , 57, 66-73		2
2030	Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. 2011 , 11, 237-41		14
2029	Physiology and pathology of nuclear phospholipase C ã. 2011 , 51, 2-12		16
2028	Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. 2011 , 105, 1684-92		409
2027	Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. 2011 , 25, 1834-9		53
2026	Acute Leukemia. 2011 , 235-250		
2025	Histamine dihydrochloride: in the management of acute myeloid leukaemia. 2011 , 71, 109-22		25
2024	Acute myeloid leukaemia: optimal management and recent developments. 2011 , 71, 1537-50		16
2023	Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge. 2011 , 11, 10-6		18

2022	Acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemias. 2011 , 289-301		1
2021	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <i>Blood</i> , 2011 , 117, 2469-75	2.2	276
2020	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. <i>Blood</i> , 2011 , 117, 2307-18	2.2	139
2019	Cancer Cytogenetics. 2011 ,		1
2018	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. 2011 , 1, e7		11
2017	Using Cytogenetic and Molecular Tests in Diagnostic Workups with the WHO Classification 2008. 2011 , 79-102		
2016	Cytogenetics of myeloproliferative neoplasms. 2011 , 730, 89-98		3
2015	Cytarabine-Induced Pulmonary Toxicity in Leukemic Patients. 2011 , 729-734		1
2014	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. 2011 , 478, 524-8		1398
2013	Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. 2011 , 43, 1012-7		424
2012	Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. 2011 , 25, 1135-61, vii		74
2011	Le sindromi mielodisplastiche: diagnosi, prognosi e terapia. 2011 , 5, 90-97		1
2010	JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. 2011 , 25, 229-37		42
2009	EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1. 2011 , 1809, 269-75		6
2008	Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. 2011 , 17, 908-15		91
2007	A small cell variant of ALK-positive, CD8-positive anaplastic large cell lymphoma with primary subcutaneous presentation mimicking subcutaneous panniculitis-like T-cell lymphoma. 2011 , 207, 522-6		6
2006	[Synchronous detection of T-cell clonality and FIP1L1-PDGFR α fusion gene in a hypereosinophilic syndrome]. 2011 , 32, e66-8		
2005	[Myelodysplastic syndrome with erythroblastopenia]. 2011 , 32, 33-8		2

2004	Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?. 2011 , 52, 1178-87	11
2003	Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature. 2011 , 11, 293-7	6
2002	Incidence of myelodysplastic syndromes in patients receiving concurrent myelosuppressive chemotherapy and pegfilgrastim. 2011 , 17, 366-71	3
2001	BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. 2011 , 11 Suppl 1, S37-45	19
2000	Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. 2011 , 365, 1384-95	890
1999	Role of flow cytometry in diagnostics of myelodysplastic syndromes--beyond the WHO 2008 classification. 2011 , 28, 273-82	18
1998	Myelodysplastic/myeloproliferative neoplasms. 2011 , 28, 283-97	15
1997	Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. 2011 , 26, 449-54	22
1996	Myelodysplastic syndromes. 2011 , 303-320	
1995	New Molecular Markers in Acute Myeloid Leukemia. 2011 ,	
1994	The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. 2011 , 43, 536-46	8
1993	Diagnosis of Acute Leukemia in Under-Resourced Laboratories. 2011 ,	2
1992	NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. 2011 , 9, 30-56	140
1991	Emerging treatments for essential thrombocythemia. 2011 , 2, 151-9	2
1990	[A case of natural killer like T cell lymphoma misdiagnosed as Behcet's Enteritis of the terminal ileum]. 2011 , 57, 365-9	3
1989	Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. 2011 , 23, 609-16	29
1988	Long-term outcome of isolated thrombocytopenia accompanied by hypocellular marrow. 2011 , 46, 128-34	1
1987	Monoclonal antibodies against nucleophosmin mutants: potentials for the detection of acute myeloid leukemia. 2011 , 8, 309-14	6

1986	Myelodysplastic syndrome: classification and changing concept. 2011 , 1, 142-150		
1985	Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. 2011 , 2011, 536062		60
1984	Leukemias. 2011 , 518-566		5
1983	Pediatric Acute Myeloid Leukemia. 2011 ,		
1982	NAD(P)H: quinone oxidoreductase 1 deficiency conjoint with marginal vitamin C deficiency causes cigarette smoke induced myelodysplastic syndromes. 2011 , 6, e20590		13
1981	In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. 2011 , 6, e21015		40
1980	Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. 2011 , 6, e26906		104
1979	Systemic mastocytosis. 2011 , 342, 409-15		15
1978	Immunohistochemistry on epoxy resin-embedded bone marrow biopsy experience with 936 cases. 2011 , 19, 15-20		4
1977	Advances in the understanding and management of primary myelofibrosis. 2011 , 23, 665-71		14
1976	Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: review of the literature. 2011 , 22, 944-7		0
1975	Therapy-related myeloid neoplasms. 2011 , 23, 672-80		37
1974	Low dose cytarabine monotherapy for myelodysplastic syndromes. 2011 ,		
1973	Immunotherapy for myeloproliferative neoplasms (MPN). 2011 , 11, 72-84		5
1972	Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 2011 , CD008238		4
1971	Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. <i>Blood</i> , 2011 , 117, 5710-8	2.2	136
1970	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. <i>Blood</i> , 2011 , 117, 2935-43	2.2	67
1969	C/EBP β and C/EBP δ proteins regulate nfkb1 and displace histone deacetylases from NF- κ B p50 homodimers to induce NF- κ B target genes. <i>Blood</i> , 2011 , 117, 4085-94	2.2	34

1968	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. <i>Blood</i> , 2011 , 117, 1109-20	2.2	178
1967	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011 , 117, 4561-8	2.2	81
1966	Overexpression of IL-3R α on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML. <i>Blood</i> , 2011 , 117, 4243-52	2.2	27
1965	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011 , 117, 7102-11	2.2	48
1964	Blood consult: resistant and progressive essential thrombocythemia. <i>Blood</i> , 2011 , 118, 240-2	2.2	6
1963	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 7007-13	2.2	54
1962	Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. <i>Blood</i> , 2011 , 117, 7121-5	2.2	154
1961	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. <i>Blood</i> , 2011 , 117, 5857-9	2.2	295
1960	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. <i>Blood</i> , 2011 , 118, 4690-3	2.2	68
1959	Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. <i>Blood</i> , 2011 , 118, 4595-8	2.2	56
1958	Hypomethylating agents for patients with myelodysplastic syndrome. 2011 ,		
1957	Hypomethylating agents for adult patients with acute myeloid leukaemia. 2011 ,		
1956	Neurologic aspects of lymphoma and leukemias. 2011 , 17, 73-94		1
1955	Acute leukemia in adults. 2011 , 17, 203-224		1
1954	Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. 2011 , 96, 221-30		73
1953	Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia. 2011 , 155, 722-4		10
1952	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. 2011 , 96, 1059-63		26
1951	Hospital care and medical utilization after discharge. 2011 , 155, 719; author reply 722		

1950	Hospital care and medical utilization after discharge. 2011 , 155, 721; author reply 722	
1949	Hospital care and medical utilization after discharge. 2011 , 155, 720; author reply 722	
1948	Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. 2011 , 341, 404-8	9
1947	Hospital care and medical utilization after discharge. 2011 , 155, 719-20; author reply 722	1
1946	Hospital care and medical utilization after discharge. 2011 , 155, 720-1; author reply 722	
1945	Hospital care and medical utilization after discharge. 2011 , 155, 721; author reply 722	1
1944	Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis. 2011 , 96, 8-10	6
1943	High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. 2011 , 96, 1548-51	55
1942	Hospital care and medical utilization after discharge. 2011 , 155, 721-2; author reply 722	
1941	Advances in therapies for acute promyelocytic leukemia. 2011 , 102, 1929-37	37
1940	JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis. 2011 , 33, 495-6; author reply 496-7	3
1939	Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia vera. 2011 , 152, 238-40	11
1938	First application of MLPA method in severe von Willebrand disease. Confirmation of a new large VWF gene deletion and identification of heterozygous carriers. 2011 , 152, 240-2	14
1937	Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. 2011 , 153, 421-36	91
1936	Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease. 2011 , 154, 278-81	5
1935	Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. 2011 , 153, 568-81	70
1934	Array-based DNA methylation profiling in acute myeloid leukaemia. 2011 , 155, 65-72	17
1933	Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice. 2011 , 155, 198-208	7

1932	Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. 2011 , 155, 599-606	86
1931	Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. 2011 , 9, 2208-14	54
1930	Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. 2011 , 162, 792-805	83
1929	Syndromes myélodysplasiques : actualité clinico-biologiques. 2011 , 2011, 13-16	
1928	Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. 2011 , 30, 1009-19	129
1927	Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. 2011 , 25, 266-70	73
1926	Synergistic induction of PI-PLC β signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. 2011 , 25, 271-80	35
1925	Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. 2011 , 25, 567-74	151
1924	Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. 2011 , 1242, 40-55	146
1923	CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness. 2011 , 33, 92-6	10
1922	Serum levels of granulocyte colony-stimulating factor in JAK2 V617F-positive vs. negative erythrocytosis. 2011 , 33, e20-1	3
1921	The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. 2011 , 86, 148-55	49
1920	Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. 2011 , 86, 512-6	2
1919	Acute myeloid leukemia detected on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in a patient with fever of unknown origin. 2011 , 30, 115-6	5
1918	Incidence of Philadelphia-chromosome in acute myelogenous leukemia and biphenotypic acute leukemia patients: And its role in their outcome. 2011 , 35, 1339-44	17
1917	Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. 2011 , 35, 1131-5	14
1916	Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. 2011 , 317, 2616-29	21
1915	Nucleophosmin gene mutations promote NIH3T3 cell migration and invasion through CXCR4 and MMPs. 2011 , 90, 38-44	10

1914	Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. 2011 , 39, 424-433.e2		26
1913	Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. 2011 , 11, 1391-401		8
1912	Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. 2011 , 25, 1825-33		64
1911	Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. 2011 , 29, 573-82		238
1910	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. <i>Blood</i> , 2011 , 118, 3932-41	2.2	265
1909	The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway. 2011 , 16, 889-901		32
1908	[Gingival hyperplasia and visual reduction]. 2011 , 108, 1039-44		2
1907	Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience. 2011 , 90, 529-37		46
1906	Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. 2011 , 90, 1037-45		28
1905	A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy. 2011 , 90, 1283-91		2
1904	Post-tonsillectomy pulmonary complication in a patient with tonsillar myeloid sarcoma. 2011 , 93, 220-223		2
1903	Acute myeloid leukemia with an unusual histologic pattern mimicking metastatic carcinoma in bone marrow: a diagnostic pitfall. 2011 , 4, 117-122		1
1902	Future therapies for the myeloproliferative neoplasms. 2011 , 6, 22-7		6
1901	Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. 2011 , 4, 19		34
1900	Current findings for recurring mutations in acute myeloid leukemia. 2011 , 4, 36		74
1899	Myelodysplastic syndrome in children: changing definitions from FAB 1976 to WHO 2008 classification systems. 2011 , 57, 1098-9		
1898	The physiology and pathology of inositide signaling in the nucleus. 2011 , 226, 14-20		26
1897	Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. 2011 , 86, 292-301		33

1896	Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. 2011 , 86, 353-6	12
1895	Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. 2011 , 86, 540-5	26
1894	Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. 2011 , 86, 490-8	40
1893	Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. 2011 , 86, 699-701	4
1892	Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. 2011 , 86, 701-2	21
1891	Laboratory and echocardiography markers in sickle cell patients with leg ulcers. 2011 , 86, 705-8	34
1890	Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. 2011 , 86, 703-5	19
1889	Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: a retrospective study. 2011 , 86, 709-10	4
1888	Acquired factor V inhibitor complicating warfarin therapy. 2011 , 86, 710-2	7
1887	Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. 2011 , 86, 712-4	5
1886	Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy. 2011 , 86, 715-6	9
1885	Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. 2011 , 86, 1013-6	21
1884	Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. 2011 , 86, 1017-26	42
1883	Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. 2011 , 63, 1188-94	61
1882	Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. 2011 , 117, 974-81	18
1881	A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 2011 , 117, 1253-61	26
1880	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. 2011 , 117, 4869-4877	44
1879	Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. 2011 , 117, 5529-37	41

1878	Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. 2011 , 117, 5074-84	21
1877	Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. 2011 , 80, 150-7	16
1876	Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 2011 , 80, 201-11	32
1875	Shooting the messenger: targeting signal transduction pathways in leukemia and related disorders. 2011 , 78, 33-44	8
1874	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. 2011 , 35, 159-62	33
1873	Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia. 2011 , 35, 957-60	6
1872	Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. 2011 , 35, 757-61	8
1871	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. 2011 , 35, 863-7	34
1870	Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. 2011 , 35, 868-73	49
1869	Transplantation for myelofibrosis: time for a randomized trial. 2011 , 35, 987-8	3
1868	Mouse models of myelodysplastic syndromes. 2011 , 35, 853-62	12
1867	Current treatment concepts of CML. 2011 , 11, 31-43	15
1866	Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. 2011 , 4, 437-52; quiz 453-4	75
1865	Ocular adnexal non-Hodgkin's lymphoma: a review of epidemiology and risk factors. 2011 , 6, 181-193	18
1864	A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. 2011 , 52, 2012-9	0
1863	Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies. 2011 , 46, 1540-4	6
1862	The dawn of the molecular era of the myelodysplastic syndromes. 2011 , 364, 2545-6	9
1861	Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. 2011 , 29, 2521-7	198

1860	Myeloid sarcoma: current approach and therapeutic options. 2011 , 2, 309-16	140
1859	Relapse of ovarian cancer with bone marrow infiltration and concurrent emergence of therapy-related acute myeloid leukemia: a case report. 2011 , 29, e295-6	2
1858	An Uncommon Variant of Acute Myeloid Leukemia: Acute Erythroid Leukemia. 2011 , 42, 644-648	1
1857	Acute basophilic leukemia associated with loss of gene ETV6 and protean complications. 2011 , 29, e623-6	10
1856	Myelodysplastic syndromes: dissecting the heterogeneity. 2011 , 29, 1937-8	9
1855	Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. 2011 , 29, 3322-7	339
1854	Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy. 2011 , 29, 349-51	28
1853	Myeloid sarcoma: clinicopathologic, cytogenetic, and outcome analysis of 21 adult patients. 2011 , 2011, 523168	9
1852	Therapy related acute myeloid leukemia with t(10:16): a rare entity. 2011 , 3, e23	3
1851	Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. 2011 , 2, 95-107	140
1850	Aggressive systemic mastocytosis associated with mesangioproliferative glomerulonephritis. 2011 , 125, 153-9	4
1849	An 8-year-old boy with hypereosinophilic syndrome. 2011 , 155 Suppl 1, 117-22	10
1848	Occurrence of BCR-ABL1-positive chronic myeloid leukemia following essential thrombocythemia. 2011 , 126, 220-3	4
1847	Essential thrombocythemia and primary myelofibrosis. 2011 , 347-359	
1846	Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 2011 , 29, 3179-84	355
1845	Bypassing the maturation arrest in myeloid cell line U937 by over-expression of microRNA-424. 2011 , 16, 298-302	20
1844	JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data. 2011 , 1, 1681-1693	1
1843	Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. 2011 , 96, 1478-87	81

1842	Myelodysplastic syndromes with bone marrow fibrosis. 2011 , 96, 180-3	29
1841	Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. 2011 , 29, 2240-6	110
1840	Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation. 2011 , 48, 182-97	22
1839	Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. 2011 , 29, 1190-7	270
1838	World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. 2011 , 2011, 250-6	37
1837	Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. 2011 , 96, 1462-9	72
1836	The Myelodysplastic Syndromes. 2011 ,	
1835	Genetic pathways leading to therapy-related myeloid neoplasms. 2011 , 3, e2011019	12
1834	Incidence of acute myeloid leukemia after breast cancer. 2011 , 3, e2011069	18
1833	Spontaneous hemopericardium leading to cardiac tamponade in a patient with essential thrombocythemia. 2011 , 2011, 247814	2
1832	Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?. 2011 , 2011, 214143	16
1831	Pitfalls in molecular diagnosis in haemato-oncology. 2011 , 64, 275-8	8
1830	Treatment-related myelodysplasia in patients with primary brain tumors. 2012 , 14, 529-40	12
1829	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. 2012 , 26, 101-5	112
1828	Lineage switching in acute leukemias: a consequence of stem cell plasticity?. 2012 , 2012, 406796	81
1827	Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players. 2012 , 2012, 925758	10
1826	A novel 11;18 translocation in a case of acute myeloid leukemia with maturation. 2012 , 18, 369-72	1
1825	The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. 2012 , 47, 639-45	59

1824	A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature. 2012 , 4, e2012017	0
1823	Autologous dendritic cells combined with cytokine-induced killer cells synergize low-dose chemotherapy in elderly patients with acute myeloid leukaemia. 2012 , 40, 1265-74	6
1822	Karyotype and DNA-Methylation Responses in Myelodysplastic Syndromes following Treatment with Traditional Chinese Formula Containing Arsenic. 2012 , 2012, 969476	8
1821	5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. 2012 , 53, 1558-60	12
1820	Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. 2012 , 18, 3293-304	35
1819	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission: have the indications changed?. 2012 , 19, 95-101	10
1818	Spontaneous remission of childhood acute marrow fibrosis and megakaryoblastic leukemia. 2012 , 34, 565-8	2
1817	Anthracycline dose intensification in young adults with acute myeloid leukemia. 2012 , 3, 17-27	7
1816	The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells. 2012 , 12, 51-63	26
1815	Emerging drugs for myelofibrosis. 2012 , 17, 555-70	3
1814	Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. 2012 , 53, 985-6	19
1813	Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. 2012 , 53, 2186-91	6
1812	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. 2012 , 97, 739-42	24
1811	Twenty Years of G-CSF. 2012 ,	6
1810	Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. 2012 , 53, 103-9	16
1809	Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. 2012 , 16, 991-5	22
1808	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. 2012 , 8, 575-93	3
1807	How to manage lower-risk myelodysplastic syndromes. 2012 , 26, 390-4	5

1806	Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: results from a multicenter validation study. 2012 , 2, e78	6
1805	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. 2012 , 26, 475-80	129
1804	How to manage the transplant question in myelofibrosis. 2012 , 2, e59	15
1803	Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. 2012 , 31, 4085-94	54
1802	JAK2 inhibitors in the treatment of myeloproliferative neoplasms. 2012 , 21, 1755-74	14
1801	Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. 2012 , 26, 943-50	30
1800	Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. 2012 , 26, 2474-82	29
1799	Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. 2012 , 26, 381-9	285
1798	IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. 2012 , 26, 693-9	49
1797	RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. 2012 , 26, 2384-9	67
1796	Comparison of CD34, CD31, and factor VIII-related antigen immunohistochemical expression in feline vascular neoplasms and CD34 expression in feline nonvascular neoplasms. 2012 , 49, 532-7	23
1795	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. 2012 , 30, 2204-10	132
1794	Protein Z concentrations in patients with acute leukemia. 2012 , 18, 542-5	7
1793	Acute leukaemia: making sense of a complex blood cancer. 2012 , 21, 76, 78-83	17
1792	From single-cell signature to prognostic factors: the case of Sezary syndrome. 2012 , 8, 699-701	1
1791	Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: the effect of isovolemic erythrocytapheresis. 2012 , 23, 455-62	12
1790	Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. 2012 , 128, 203-12	9
1789	Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia. 2012 , 127, 63-71	14

1788	Management of myelofibrosis: a survey of current practice in the United Kingdom. 2012 , 65, 1124-7	1
1787	Acute myeloid leukemia: focus on novel therapeutic strategies. 2012 , 6, 205-17	23
1786	Myeloid neoplasias: what molecular analyses are telling us. 2012 , 2012, 321246	2
1785	Thrombosis in hematologic malignancies: risks and consequences. 2012 , 1, 87-95	
1784	Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sjögren syndrome. 2012 , 157, 159-67	10
1783	JAK 2V617F Mutation: Frequency and Relation to Clinical and Laboratory Features of BCR-ABL Negative Myeloproliferative Diseases. 2012 , 22, 77-84	2
1782	Cytogenetic risk stratification in myelodysplastic syndromes: are we there yet?. 2012 , 30, 2703-4; author reply 2704-5	10
1781	Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. 2012 , 3, 105-16	8
1780	Myelodysplasia and autoimmunity. 2012 , 24, 97-102	26
1779	Evaluation of the immature myeloid information (IMI) by Sysmex XE 2100 hematology analyzer in the identification of blasts of myeloid lineage. 2012 , 50, 1861-4	1
1778	Primary intracerebral myeloid sarcoma. 2012 , 35, 694-7	6
1777	Trisomy 8 is the most frequent cytogenetic abnormality in de novo myelodysplastic syndrome in China. 2012 , 35, 100-6	9
1776	Prognostic significance of HOXB4 in de novo acute myeloid leukemia. 2012 , 17, 125-31	11
1775	Thrombopoietin mimetics for patients with myelodysplastic syndromes. 2012 ,	2
1774	Successful treatment of childhood hypocellular acute myeloid leukemia. 2012 , 34, 398-401	1
1773	Prise en charge thérapeutique des leucémies aiguës myéloblastiques. 2012 , 7, 1-17	
1772	Nuclear PI-PLC and myelodysplastic syndromes: genetics and epigenetics. 2012 , 18, 1751-4	8
1771	Classification et facteurs pronostiques des leucémies aiguës. 2012 , 7, 1-17	2

- 1770 t(6;9)(p23;q34) presenting acute myeloid leukemia in a child with an unsuspected 45,X/46,X,derY [?t(Yp;Yq)] chromosomal constitution: yet another Y chromosome overdosage and malignancy association. **2012**, 34, e237-40
- 1769 Improving circulatory disturbance in transient abnormal myelopoiesis. **2012**, 34, e149-51 4
- 1768 Research Highlights: Highlights from the latest articles in molecular profiling and prognosis in acute myeloid leukemia. **2012**, 9, 679-682
- 1767 Acute myeloid leukemia developing in patients with autoimmune diseases. **2012**, 97, 805-17 50
- 1766 Cytogenetics of acute leukemias. 135-167
- 1765 Acute myeloid leukemia. 395-420 1
- 1764 Unusual Myelodysplastic Syndromes and Myeloproliferative Neoplasms. **2012**, 613-616
- 1763 Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome. **2012**, 227, 119-28 19
- 1762 European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. *Haematologica* 2012;97(3):360-5--comment. **2012**, 97, e5-6; discussion e7-8 11
- 1761 Cytogenetic and morphological analysis of de novo acute myeloid leukemia in adults: a single center study in Jordan. **2012**, 15, 5-10 5
- 1760 Therapy-related myeloid neoplasms following treatment with radioiodine. **2012**, 97, 206-12 32
- 1759 Current insights in the cellular and molecular biology of chronic myelomonocytic leukemia. **2012**, 1, 147-158 1
- 1758 Infections in myelodysplastic syndromes. **2012**, 97, 1459-70 59
- 1757 Leucémies aiguës de l'adulte. **2012**, 7, 1-9
- 1756 Numb chin syndrome in acute myeloid leukemia. **2012**, 344, 237-40 5
- 1755 Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. **2012**, 97, 915-8 24
- 1754 Essential thrombocythemia: new advances in an old disease. **2012**, 2, 603-614 1
- 1753 Efficacy of vorinostat in a murine model of polycythemia vera. *Blood*, **2012**, 119, 3779-89 2.2 40

1752	Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. 2012 , 647-658		1
1751	Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. <i>Blood</i> , 2012 , 119, 1532-42	2.2	47
1750	Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. <i>Blood</i> , 2012 , 119, 55-63	2.2	22
1749	Unique features of primary myelofibrosis in Chinese. <i>Blood</i> , 2012 , 119, 2469-73	2.2	25
1748	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. <i>Blood</i> , 2012 , 119, e96-9	2.2	60
1747	Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. <i>Blood</i> , 2012 , 120, 1290-8	2.2	123
1746	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 5980-8	2.2	61
1745	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. <i>Blood</i> , 2012 , 120, 4168-71	2.2	128
1744	Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 4945-51	2.2	105
1743	Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. 2012 , 97, 1218-24		74
1742	Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. 2012 , 97, 1209-17		110
1741	Ruxolitinib for myelofibrosis. 2012 , 2, 1023-1031		
1740	Decitabine for acute myeloid leukemia. 2012 , 12, 299-305		10
1739	Clonal chromosome anomalies affecting FLI1 mimic inherited thrombocytopenia of the Paris-Trousseau type. 2012 , 89, 345-9		6
1738	Childhood acute myeloid leukaemia. 2012 , 159, 259-76		59
1737	Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia. 2012 , 89, 430-1		2
1736	Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. 2012 , 158, 581-8		24
1735	Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. 2012 , 40, 771-780.e19		45

1734	Update on cytogenetic and molecular changes in myelodysplastic syndromes. 2012 , 53, 525-36	19
1733	A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine. 2012 , 128, 1-6	6
1732	[Bone marrow histology from the clinical point of view]. 2012 , 33, 490-5	1
1731	Le diagnostic de la leucémie myéloblastique chronique (LMC) en 2012. 2012 , 14, 561-568	
1730	DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis. 2012 , 109, 415-23	12
1729	One thousand patients with primary myelofibrosis: the mayo clinic experience. 2012 , 87, 25-33	137
1728	Współczesne leczenie pierwotnej mielofibrozy. 2012 , 43, 107-112	
1727	An extremely rare lineage switch from T-cell lymphoblastic lymphoma into B-cell acute lymphoblastic leukemia at relapse. 2012 , 43, 369-371	
1726	Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. 2012 , 21, 1604-15	41
1725	Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms. 2012 , 53, 2496-7	13
1724	Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. 2012 , 53, 2214-7	9
1723	Cyclohexyl analogues of ethylenediamine dipropanoic acid induce caspase-independent mitochondrial apoptosis in human leukemic cells. 2012 , 25, 931-9	18
1722	New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy. 2012 , 18, 5163-71	12
1721	Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. 2012 , 91, 1887-95	9
1720	Revised international prognostic scoring system for myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 2454-65	1799
1719	Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. 2012 , 125, S6-13	38
1718	Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction. 2012 , 125, S26-30	7
1717	Erythroid proliferations in myeloid neoplasms. 2012 , 43, 153-64	23

1716	Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. 2012 , 205, 18-24		18
1715	A cytogenetic study of 397 consecutive acute myeloid leukemia cases identified three with a t(7;21) associated with 5q abnormalities and exhibiting similar clinical and biological features, suggesting a new, rare acute myeloid leukemia entity. 2012 , 205, 365-72		16
1714	Recent decline in the U.S. death rate from myeloproliferative neoplasms, 1999-2006. 2012 , 36, 133-6		5
1713	Adult acute leukemia. 2012 , 58, 219-38		26
1712	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012 , 120, 3187-205	2.2	359
1711	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. 2012 , 30, 4515-23		310
1710	Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. 2012 , 87, 1003-5		79
1709	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 2012 , 87, 1010-6		52
1708	Chromosome anomalies in bone marrow as primary cause of aplastic or hypoplastic conditions and peripheral cytopenia: disorders due to secondary impairment of RUNX1 and MPL genes. 2012 , 5, 39		1
1707	Outcome of therapy-related myeloid neoplasms treated with azacitidine. 2012 , 5, 44		37
1706	Myeloid leukemia cutis in the setting of myelodysplastic syndrome: a crucial dermatological diagnosis. 2012 , 51, 383-8		17
1705	Flow Cytometric Immunophenotyping as Diagnostic Tool of Hematopoietic Malignancies. 2012 , 143-160		1
1704	Leukemias. 2012 , 159-194		
1703	Loss of the tumor suppressor BAP1 causes myeloid transformation. 2012 , 337, 1541-6		290
1702	Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. 2012 , 26, 1842-9		33
1701	Ruxolitinib: in the treatment of myelofibrosis. 2012 , 72, 2117-27		23
1700	Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors. 2012 , 32, 423-6		3
1699	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012 , 120, 569-71	2.2	60

1698	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade. 2012 , 8, 373-81	5
1697	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. 2012 , 13, 2397-407	30
1696	Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. 2012 , 49, 330-41	31
1695	An optimized technology platform for the rapid multiplex molecular analysis of genetic alterations associated with leukemia. 2012 , 205, 488-500	7
1694	A novel RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with a t(11;21)(p14;q22). 2012 , 205, 608-11	6
1693	Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. 2012 , 12, 207-12	26
1692	Flow cytometry to distinguish myelodysplastic syndromes from non-neoplastic causes of cytopenia: ready for prime time?. 2012 , 36, 1089-90	0
1691	Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. 2012 , 36, 1147-51	39
1690	Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. 2012 , 36, 1229-36	12
1689	Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993-2007. 2012 , 36, 1262-6	8
1688	Management of AML: who do we really cure?. 2012 , 36, 1475-80	11
1687	Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. 2012 , 36, 1481-9	13
1686	[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations]. 2012 , 138, 119.e1-9	1
1685	[Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms]. 2012 , 139, 373-8	3
1684	TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. 2012 , 7, e31605	66
1683	Update on the science of myelodysplastic syndromes. 2012 , 16 Suppl, 9-22	2
1682	Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?. 2012 , 5, 395-407	9
1681	Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. 2012 , 53, 1352-9	66

1680 Management of Myelodysplastic Syndromes and Acute Leukaemia. **2012**, 375-385

1679 Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. **2012**, 7, 310-20 63

1678 Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia. **2012**, 29, 2063-9 9

1677 Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. **2012**, 29, 2359-63 11

1676 The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. **2012**, 29, 2379-84 10

1675 Erythroleukemia in a retrovirus-negative cat. **2012**, 240, 294-7 6

1674 FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia. **2012**, 96, 234-40 6

1673 Phosphoinositides and Disease. **2012**, 1

1672 Prognostic features of patients with myelodysplastic syndromes aged 2012, 53, 2439-43 6

1671 Myelodysplasien. **2012**, 18, 1120-1129

1670 Myeloproliferative Neoplasien. **2012**, 7, 34-44

1669 Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review. **2012**, 127, 124-7 26

1668 Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome. **2012**, 91, 1979-81 16

1667 Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia. **2012**, 91, 1555-62 8

1666 Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches. **2012**, 91, 1351-62 15

1665 Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. **2012**, CD008238 19

1664 Therapy with JAK2 inhibitors for myeloproliferative neoplasms. **2012**, 26, 1083-99 16

1663 Rapid detection of neoplastic cells in serous cavity effusions in children with flow cytometry immunophenotyping. **2012**, 53, 1509-14 7

1662	Leukemia and Related Disorders. 2012,	3
1661	[Myelodysplastic syndromes]. 2012, 33 Suppl 2, A21-3	0
1660	Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. 2012, 49, 422-8	72
1659	Molecular Aspects of Hematologic Malignancies. 2012,	2
1658	Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. 2012, 16, 269-83	13
1657	Identification of JAK2 as a mediator of FIP1L1-PDGFR α -induced eosinophil growth and function in CEL. 2012, 7, e34912	25
1656	Single nucleotide polymorphism (SNP)-based loss of heterozygosity (LOH) testing by real time PCR in patients suspect of myeloproliferative disease. 2012, 7, e38362	5
1655	Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. 2012, 7, e41485	22
1654	BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. 2012, 3, 490-501	66
1653	An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. 2012, 6, e8	104
1652	Cytogenetics in Hematooncology. 2012,	
1651	Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. 2012,	1
1650	RET: A Multi-Faceted Gene in Human Cancer. 2012, 27, 173	
1649	Congenital Malignant Disorders. 2012, 1143-1163	1
1648	Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. 2012, 97, 123-7	26
1647	Approach to the diagnosis and classification of blood diseases. 2012, 549-562	1
1646	Bone marrow fibrosis and metastatic prostate adenocarcinoma. 2012, 2012,	
1645	The spectrum of JAK2-positive myeloproliferative neoplasms. 2012, 2012, 561-566	27

1644	Recent developments in myelofibrosis. 2012 , 125		2
1643	B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phenotype acute leukemia with additional chromosomal aberrations in the course of therapy. 2012 , 4, e15		5
1642	Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification. 2012 ,		
1641	Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. 2012 , 97, 1904-8		39
1640	Ruxolitinib for the treatment of myelofibrosis: its clinical potential. 2012 , 8, 95-103		29
1639	A systematic review of validated methods for identifying lymphoma using administrative data. 2012 , 21 Suppl 1, 203-12		19
1638	The U.S. Food and Drug Administration's Mini-Sentinel Program. 2012 , 21, 1-303		150
1637	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. <i>Blood</i> , 2012 , 119, 3203-10	2.2	293
1636	Leukemia risk models in primary myelofibrosis: an International Working Group study. 2012 , 26, 1439-41		37
1635	Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes. 2012 , 12, 253-64		17
1634	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. <i>Blood</i> , 2012 , 119, 3211-8	2.2	188
1633	ALKoma: a cancer subtype with a shared target. 2012 , 2, 495-502		141
1632	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 249-58	2.2	58
1631	Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC. 2012 , 97, 241-5		18
1630	Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. 2012 , 91, 671-677		15
1629	Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group. 2012 , 58, 519-24		50
1628	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. 2012 , 51, 743-55		119
1627	Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. 2012 , 51, 890-7		25

1626	Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience. 2012 , 30, 76-81	20
1625	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. 2012 , 26, 1908-75	557
1624	Bleeding and thrombosis in acute promyelocytic leukemia. 2012 , 87, 596-603	74
1623	Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 610-9	37
1622	Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. 2012 , 87, 659-62	55
1621	Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. 2012 , 87, 669-72	44
1620	Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. 2012 , 87, 684-6	23
1619	Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. 2012 , 87, 692-701	62
1618	Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. 2012 , 118, 5550-9	28
1617	Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis. 2012 , 81, 718-24	16
1616	Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension. 2012 , 81, 776-84	22
1615	Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. 2012 , 30, 1087-94	22
1614	Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases. 2012 , 51, 136-8	5
1613	How to manage children and young adults with myeloproliferative neoplasms. 2012 , 26, 1452-7	28
1612	Diagnostic work-up for clinical and prognostic assessment of acute leukaemia. 2012 , 8, 26-35	0
1611	ABVD vs. radiotherapy in early stage Hodgkin's lymphoma: A critical look at the NCIC HD.6 trial. 2012 , 188, 649-52	1
1610	Clinical features and prognostic factors of Asian patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. 2012 , 91, 1121-8	19
1609	Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany. 2012 , 138, 953-7	2

1608	Not so benign haematology: anaemia of the elderly. 2012 , 156, 173-85	45
1607	Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. 2012 , 156, 619-25	30
1606	Aortic valve replacement in patients with systemic mastocytosis. 2012 , 27, 189-91	7
1605	Leukemia cutis - epidemiology, clinical presentation, and differential diagnoses. 2012 , 10, 27-36	30
1604	Leukaemia cutis [Epidemiologie, Klinik und Differenzialdiagnosen. 2012 , 10, 27-37	19
1603	Mice heterozygous for CREB binding protein are hypersensitive to γ -radiation and invariably develop myelodysplastic/myeloproliferative neoplasm. 2012 , 40, 295-306.e5	25
1602	Treatment of acute lymphoblastic leukemia in adults. 2012 , 81, 94-102	27
1601	Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. 2012 , 39, 67-73	37
1600	Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights. 2012 , 39, 37-46	14
1599	Trends and distribution of oral and pharyngeal lymphoma in Israel. 2012 , 18, 700-6	3
1598	Molecular and genetic features of myelodysplastic syndromes. 2012 , 34, 215-22	23
1597	Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis. 2012 , 15, 86-94	6
1596	Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog. 2012 , 41, 362-368	19
1595	SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis. 2012 , 36, 281-6	20
1594	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. 2012 , 36, 287-92	16
1593	Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature. 2012 , 36, e52-6	1
1592	Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. 2012 , 36, 264-70	17
1591	Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. 2012 , 36, 401-6	28

1590	Rare tetraploidy with large 5q deletion in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). 2012 , 36, e68-70	3
1589	Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies. 2012 , 36, 682-3	1
1588	Cytogenetics in myelodysplastic syndromes: old methods, new clues. 2012 , 36, 806-7	1
1587	The place of sideroblastic erythropoiesis in WHO 2008 classification of MDS; RCMD versus RCMD-RD as combined or a separate entity?. 2012 , 36, 811-2	
1586	Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. 2012 , 36, 998-1003	30
1585	Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. 2012 , 36, 1071-3	45
1584	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. 2012 , 157, 426-37	18
1583	Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival. 2012 , 158, 99-107	6
1582	Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. 2012 , 158, 242-248	53
1581	Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome. 2012 , 158, 293-296	8
1580	De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics. 2012 , 158, 129-37	7
1579	Guideline for the diagnosis and management of myelofibrosis. 2012 , 158, 453-71	76
1578	Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes. 2012 , 7, 19	11
1577	Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. 2012 , 82, 3-8	47
1576	Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. 2012 , 51, 54-65	21
1575	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. 2012 , 118, 127-33	36
1574	Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIb/IIIa versus GPIIb/IIIa antibodies. 2012 , 87, 206-8	67
1573	Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. 2012 , 87, 211-3	3

1572	The potential role of pre-transplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network. 2012 , 87, 213-7	13
1571	TP53 mutations and polymorphisms in primary myelofibrosis. 2012 , 87, 204-6	10
1570	Practical approach for characterization of glucose 6-phosphate dehydrogenase (G6PD) deficiency in countries with population ethnically heterogeneous: description of seven new G6PD mutants. 2012 , 87, 208-10	3
1569	Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. 2012 , 87, 217-9	27
1568	Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant. 2012 , 87, 219-21	20
1567	Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. 2012 , 87, 221-3	19
1566	Complications of implantable venous access devices in patients with sickle cell disease. 2012 , 87, 224-6	16
1565	Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma. 2012 , 87, 226-8	7
1564	Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer. 2012 , 87, 230-2	1
1563	The diagnostic value of biopsy of small peripheral lymph nodes in patients with suspected lymphoma. 2012 , 87, 228-30	2
1562	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 2012 , 87, 203-4	22
1561	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 89-99	118
1560	Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 285-93	125
1559	Prognostication in primary myelofibrosis. 2012 , 7, 43-9	17
1558	Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?. 2012 , 7, 78-86	28
1557	Role of TET2 mutations in myeloproliferative neoplasms. 2012 , 7, 57-64	26
1556	Combination strategies in myelodysplastic syndromes. 2012 , 95, 26-33	20
1555	[Childhood-onset mastocytosis]. 2012 , 63, 104-9	8

1554	Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. 2012 , 91, 1-7	12
1553	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. 2012 , 91, 519-25	86
1552	Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. 2013 , 54, 138-44	90
1551	A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints. 2013 , 6, 18	3
1550	Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. 2013 , 6, 29	45
1549	DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population. 2013 , 6, 9	12
1548	Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. 2013 , 14, R37	49
1547	Thoracic t(9;22)-positive granulocytic sarcoma as initial presentation of chronic myeloid leukemia. 2013 , 13, 619-21	4
1546	Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. 2013 , 92, 19-24	46
1545	Acute Leukaemia. 2013 , 43-99	
1544	Cancer Genomics. 2013 ,	4
1543	Nuclear Medicine Therapy. 2013 ,	3
1542	Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. 2013 , 73, 1183-96	7
1541	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. 2013 , 3, e122	10
1540	The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 2013 , 27, 1891-901	108
1539	AKT is a therapeutic target in myeloproliferative neoplasms. 2013 , 27, 1882-90	51
1538	Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia. 2013 , 15, 678-86	8
1537	Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection. 2013 , 13, 206	11

1536 WHO Classification of Leukemia. **2013**, 329-336

1535 Leukemias, Lymphomas, and Other Related Disorders. **2013**, 1-44

1

1534 Individualisierte Medizin in der Diagnostik und prognostischen Einschätzung in der akuten myeloischen Leukämie mit normalem Karyotyp bei Erwachsenen unter 65 Jahren: eine systematische Literaturrecherche und Metaanalyse zu FLT3-ITD. **2013**, 25, 183-193

1533 Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications. **2013**, 6, 32-36

1532 Therapy-related MDS: the importance of repeating cytogenetics and immunophenotyping in Relapsed AML. **2013**, 6, 207-211

3

1531 MiR-424 regulates monocytic differentiation of human leukemia U937 cells by directly targeting CDX2. **2013**, 35, 1799-806

11

1530 Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). **2013**, 31, 1023-34

38

1529 Novel Molecular Acquisitions in Leukemias. **2013**, 453-493

1528 The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems. **2013**, 54, 2588-91

2

1527 Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine. **2013**, 88, 780-3

14

1526 Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. **2013**, 92, 1617-23

34

1525 Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. **2013**, 92, 1543-52

15

1524 The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. **2013**, 92, 1335-43

18

1523 Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. **2013**, 92, 1201-6

11

1522 Sustained complete remission in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm following autologous peripheral blood stem cell transplantation. **2013**, 92, 1285-6

5

1521 Morphology and quantitative composition of hematopoietic cells in murine bone marrow and spleen of healthy subjects. **2013**, 92, 587-94

26

1520 Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia. **2013**, 92, 451-7

23

1519 Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. **2013**, 92, 25-32

20

1518	Using Cytogenetic Rearrangements for Cancer Prognosis and Treatment (Pharmacogenetics). 2013 , 1, 99-112	5
1517	Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients. 2013 ,	10
1516	Detection of MPL mutations by a novel allele-specific PCR-based strategy. 2013 , 15, 810-8	31
1515	[Burkitt's leukemia presenting as atypical acute mastoiditis in a 7-month-old child]. 2013 , 20, 1317-20	10
1514	[Chronic myeloid leukemia]. 2013 , 59, 220-32	2
1513	Acute leukaemia. 2013 , 41, 269-274	0
1512	Income and outcome in myelodysplastic syndrome: the prognostic impact of SES in a single-payer system. 2013 , 37, 1495-501	2
1511	Parotid gland lymphoma: prognostic analysis of 2140 patients. 2013 , 123, 1199-203	38
1510	Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. 2013 , 13, 435-40	23
1509	Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. 2013 , 13, 711-5	39
1508	Practical management of patients with myelofibrosis receiving ruxolitinib. 2013 , 6, 511-23	24
1507	The new landscape of therapy for myelofibrosis. 2013 , 8, 325-32	12
1506	World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience. 2013 , 88, 1012-6	39
1505	Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. 2013 , 31, 3557-64	39
1504	Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis. 2013 , 27, 2149-56	11
1503	DNA methyltransferases in hematologic malignancies. 2013 , 50, 48-60	36
1502	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. 2013 , 31, 3883-8	35
1501	Standardizing the initial evaluation for myelodysplastic syndromes. 2013 , 8, 361-9	4

1500	Genomic medicine: a decade of successes, challenges, and opportunities. 2013 , 5, 189sr4		165
1499	The impact of trisomy 21 on foetal haematopoiesis. 2013 , 51, 277-81		16
1498	Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?. 2013 , 26, 387-400		11
1497	Increased Th22 cells as well as Th17 cells in patients with adult T-cell acute lymphoblastic leukemia. 2013 , 426, 108-13		18
1496	WHO classification of myeloproliferative neoplasms (MPN): A critical update. 2013 , 8, 333-41		14
1495	Myelodysplastic syndromes should be renamed as myelodysplastic neoplasms. 2013 , 37, 463-4		1
1494	Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. 2013 , 27, E21-9		15
1493	Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. 2013 , 88, 967-74		22
1492	Myelodysplastic Syndromes/Neoplasms Overview. 2013 , 111-127		
1491	The biology and clinical impact of genetic lesions in myeloid malignancies. <i>Blood</i> , 2013 , 122, 3741-8	2.2	37
1490	[New tools and treatments in myelodysplastic syndromes]. 2013 , 34, 159-67		0
1489	A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 2013 , 84, 71-81		6
1488	Abstracts of the Lectures During Haematocon 2013. 2013 , 29, 191-277		1
1487	Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. 2013 , 6, 73		21
1486	Essential thrombocythaemia: a single institution experience of 16 years. 2013 , 29, 139-46		3
1485	Myeloproliferative Neoplasms and Myelodysplastic Syndromes: Molecular Diagnostics. 2013 , 929-944		
1484	Lateral pharyngeal wall myeloid sarcoma as a relapse of acute biphenotypic leukemia: a case report and review of the literature. 2013 , 7, 292		4
1483	Endoscopic findings of lymphomas of the stomach. 2013 , 13, 174		17

1482	Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes. 2013 , 98, 687-93		4
1481	There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. 2013 , 8, 351-60		31
1480	Genetic basis of MPN: Beyond JAK2-V617F. 2013 , 8, 299-306		15
1479	Rapid diagnosis and prognosis of de novo acute myeloid leukemia by serum metabonomic analysis. 2013 , 12, 4393-401		55
1478	Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome. 2013 , 27, 1291-300		11
1477	Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure. 2013 , 48, 678-83		14
1476	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). 2013 , 37, 637-40		40
1475	Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. 2013 , 37, 510-5		16
1474	Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. 2013 , 88, 831-7		35
1473	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. 2013 , 88, 690-3		29
1472	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. 2013 , 27, 2084-6		39
1471	Addition of Bercaptoethanol is a prerequisite for high-quality RNA isolation using QIAasympyphony technology as demonstrated by detection of molecular aberrations in hematologic malignancies. 2013 , 17, 475-80		3
1470	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i> , 2013 , 122, 4047-53	2.2	328
1469	Clinical and biological implications of driver mutations in myelodysplastic syndromes. <i>Blood</i> , 2013 , 122, 3616-27; quiz 3699	2.2	1169
1468	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013 , 122, 2943-64	2.2	437
1467	Skeletal morbidity is strongly associated with poor prognosis in adult acute lymphoblastic leukemia. 2013 , 54, 117-22		1
1466	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. 2013 , 45, 18-24		272
1465	Genetic profiling in acute myeloid leukaemia--where are we and what is its role in patient management. 2013 , 160, 303-20		44

1464	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013 , 121, 2424-31	2.2	75
1463	Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. 2013 , 54, 1527-31		9
1462	Acute Myeloid Leukemia Overview. 2013 , 219-226		
1461	Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. 2013 , 27, 610-8		29
1460	Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution. 2013 , 88, 120-9		14
1459	Ruxolitinib: a new treatment option for myelofibrosis. 2013 , 33, 84-92		17
1458	Chronic myeloid leukemia. 2013 , 59, 220-232		
1457	Molecular diagnosis of hematopoietic neoplasms. 2013 , 33, 817-33		1
1456	Current pathology practices in and barriers to MDS diagnosis. 2013 , 37, 1656-61		10
1455	[Spontaneous remission of bone marrow aplasia associated with chromosome 8 trisomy, with subsequent evolution to acute monoblastic leukemia and recurrence of the clonal abnormality]. 2013 , 141, 42-3		
1454	Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. 2013 , 13 Suppl 2, S276-81		4
1453	Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. 2013 , 37, 312-9		4
1452	A novel t(4;16)(q25;q23.1) associated with EGF and ELOVL6 deregulation in acute myeloid leukemia. 2013 , 529, 144-7		7
1451	Leczenie celowane w ostrych białczkach szpikowych. 2013 , 44, 85-92		
1450	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. 2013 , 37, 520-30		15
1449	Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative. 2013 , 37, 422-6		3
1448	Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. 2013 , 37, 609-13		90
1447	Mice lacking the sodium-dependent phosphate import protein, PiT1 (SLC20A1), have a severe defect in terminal erythroid differentiation and early B cell development. 2013 , 41, 432-43.e7		17

1446	CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome. 2013 , 37, 907-10	27
1445	Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. 2013 , 105, 1540-9	60
1444	Emerging drugs for polycythemia vera. 2013 , 18, 393-404	7
1443	Prognostic score including gene mutations in chronic myelomonocytic leukemia. 2013 , 31, 2428-36	373
1442	The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. 2013 , 11, 815-27	54
1441	[Prediction of frailty fractures or prediction of densitometric osteoporosis. That is the question!]. 2013 , 141, 43-4	3
1440	Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome. 2013 , 48, 397-401	3
1439	Update on Myelodysplastic Syndromes Classification and Prognosis. 2013 , 6, 693-728	1
1438	Znaczenie modyfikacji epigenetycznych w patogenezie białczek. 2013 , 44, 48-57	1
1437	Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. 2013 , 37, 877-82	30
1436	Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. 2013 , 37, 862-7	10
1435	Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. 2013 , 37, 1690-6	29
1434	Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. 2013 , 37, 569-74	8
1433	Ostra białczka o mieszanym fenotypie [jak rozpoznać jak leczyć]. 2013 , 44, 215-221	
1432	Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. 2013 , 13, 559-67	44
1431	A novel acidic serine protease, ASPNJ inhibits proliferation, induces apoptosis and enhances chemo-susceptibility of acute promyelocytic leukemia cell. 2013 , 37, 1697-703	4
1430	Using functional genomics to overcome therapeutic resistance in hematological malignancies. 2013 , 55, 100-15	7
1429	Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome. 2013 , 30, 341	8

1428	HLA-G expression in acute lymphoblastic leukemia: a significant prognostic tumor biomarker. 2013 , 30, 460	17
1427	New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. 2013 , 19, 1637-43	16
1426	The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?. 2013 , 6, 59-68	13
1425	New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. 2013 , 52, 385-401	13
1424	Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes. 2013 , 90, 111-20	14
1423	Growth control and ribosomopathies. 2013 , 23, 63-71	83
1422	Thrombocytosis and Essential Thrombocythemia. 2013 , 999-1017	
1421	Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia. 2013 , 305-329	4
1420	Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. 2013 , 213-239	
1419	Diagnosis and Treatment of Childhood Acute Myeloid Leukemia. 2013 , 355-373	1
1418	The Myelodysplastic Syndromes. 2013 , 487-518	1
1417	Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. 2013 , 92, 747-58	44
1416	Genetic and epigenetic alterations of myeloproliferative disorders. 2013 , 97, 183-97	47
1415	Radionuclide Therapy of Leukemias. 2013 , 27-47	
1414	Myelodysplasia: new approaches. 2013 , 14, 156-69	4
1413	Therapy-Related Acute Myelogenous Leukemia. 2013 , 455-486	1
1412	Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. 2013 , 161, 339-47	67
1411	Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasia. 2013 , 8, e53624	3

1410	Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. 2013 , 109, 1025-32	48
1409	Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. 2013 , 27, 1953-8	51
1408	Acute myeloid leukaemia in adults. 2013 , 381, 484-95	360
1407	Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. 2013 , 27, 836-42	39
1406	Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. 2013 , 54, 2537-9	16
1405	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. 2013 , 54, 1228-34	31
1404	Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. 2013 , 93, 252-9	177
1403	Decitabine: a review of its use in older patients with acute myeloid leukaemia. 2013 , 30, 447-58	12
1402	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. 2013 , 161, 508-16	69
1401	Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA. 2013 , 59, 1238-50	16
1400	Foundational concepts of cell fate conversion to the hematopoietic lineage. 2013 , 23, 585-90	2
1399	Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia. 2013 , 54, 2660-6	20
1398	Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia. 2013 , 37, 868-71	10
1397	Fludarabine: a review of the clear benefits and potential harms. 2013 , 37, 986-94	33
1396	Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?. 2013 , 41, 665-74	28
1395	[Myeloproliferative neoplasms related glomerulopathy]. 2013 , 34, 369-72	0
1394	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. 2013 , 90, 355-64	52
1393	Mutations and prognosis in primary myelofibrosis. 2013 , 27, 1861-9	520

1392	Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. 2013 , 88, 507-16	92
1391	[Myelodysplastic syndromes]. 2013 , 54, 699-708	
1390	Loeffler's endomyocarditis: from cardiac arrest to complete recovery. 2013 , 31, 271.e1-3	2
1389	Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome. 2013 , 37, 71-5	17
1388	The diagnosis and management of erythrocytosis. 2013 , 347, f6667	48
1387	Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation. 2013 , 48, 390-5	9
1386	Prognostic models in myelodysplastic syndromes. 2013 , 2013, 504-10	22
1385	Refractory anemia with ring sideroblasts. 2013 , 26, 377-85	30
1384	Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon- α therapy. 2013 , 18, 922-6	4
1383	In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping. 2013 , 13, 29-48	7
1382	Update on the treatment of Ph-negative myeloproliferative neoplasms. 2013 , 2, 251-262	1
1381	Sideroblastic Anemias: Molecular Basis, Pathophysiology, and Clinical Aspects. 2013 , 43-87	5
1380	Treatment options for myelofibrosis and myeloproliferative neoplasia. 2013 , 2, 487-495	
1379	Development of a curative treatment within the AML-BFM studies. 2013 , 225 Suppl 1, S79-86	15
1378	Research Highlights. 2013 , 10, 531-533	
1377	Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?. 2013 , 38, 73-84	12
1376	Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. 2013 , 98, 119-28	68
1375	Heterogeneity in the myelodysplastic syndromes: moving toward a better understanding. 2013 , 54, 907-8	

1374	Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. 2013 , 35, 581-8	25
1373	Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy. 2013 , 5, e2013050	6
1372	Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan. 2013 , 43, 1177-83	1
1371	JAK2 V617F Mutation in Iranian Patients with Myeloproliferative Neoplasms: Clinical and Laboratory Findings. 2013 ,	0
1370	Bilateral metachronous testicular chloroma: a rare clinical entity. 2013 , 5, 992-3	1
1369	Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. 2013 , 125, 128-35	36
1368	Late-onset X-linked dominant protoporphyria: an etiology of photosensitivity in the elderly. 2013 , 133, 1688-90	10
1367	The evolving molecular genetic landscape in acute myeloid leukaemia. 2013 , 20, 79-85	48
1366	Socioeconomic status, area remoteness, and survival from childhood leukemia: results from the Nationwide Registry for Childhood Hematological Malignancies in Greece. 2013 , 22, 473-9	22
1365	Biology and management of therapy-related acute promyelocytic leukemia. 2013 , 25, 695-700	12
1364	Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders. 2013 , 14, 308-14	8
1363	A simplified flow cytometric immunophenotyping procedure for the diagnosis of effusions caused by epithelial malignancies. 2013 , 139, 672-81	23
1362	Decitabine for the treatment of adult patients (age \geq 5 years) with newly diagnosed de novo secondary acute myeloid leukemia. 2013 , 2, 305-314	
1361	Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. 2013 , 19, 3297-308	50
1360	Clinical Presentation and Differential Diagnosis. 2013 , 3-8	
1359	Hematopoietic Tumors. 2013 , 608-678	3
1358	A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers. 2013 , 12, 626-37	61
1357	Posterior Pole Manifestations of Hematologic Diseases. 2013 , 425-450	

1356	Importance of genetics in the clinical management of chronic myelomonocytic leukemia. 2013 , 31, 2374-6	9
1355	Translocation t(5;18)(q35;q21) as a rare nonrandom abnormality in acute myeloid leukemia. 2013 , 139, 289-94	3
1354	Early precursor T-lymphoblastic leukaemia/lymphoma arising from paediatric chronic myeloid leukaemia - unusual lymph node blast crisis. 2013 , 161, 136-9	6
1353	Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. 2013 , 162, 517-24	43
1352	Epidemiology and risk factors for infections in myelodysplastic syndromes. 2013 , 15, 652-7	13
1351	A pipeline with multiplex reverse transcription polymerase chain reaction and microarray for screening of chromosomal translocations in leukemia. 2013 , 2013, 135086	2
1350	Molecular basis and clonal evolution of myeloproliferative neoplasms. 2013 , 51, 1889-96	7
1349	Development of a high-resolution melting analysis for the detection of the SF3B1 mutations. 2013 , 17, 342-7	9
1348	Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review. 2013 , 2, 889-98	23
1347	Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. 2013 , 91, 228-35	17
1346	Outcome of poor response paediatric AML using early SCT. 2013 , 90, 187-94	10
1345	Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases. 2013 , 1, 246-59	12
1344	Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). 2013 , 91, 361-8	32
1343	A surprising cause of masses in the chest. 2013 , 88, 518-21	
1342	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. 2013 , 163, 214-22	28
1341	Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. 2013 , 88, 741-6	10
1340	Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome. 2013 , 84, 370-8	16
1339	Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. 2013 , 88, 312-6	51

1338	Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. 2013 , 129, 48-54		2
1337	Functional and cancer genomics of ASXL family members. 2013 , 109, 299-306		93
1336	Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. 2013 , 54, 1989-95		53
1335	Monitoring NK cell activity in patients with hematological malignancies. 2013 , 2, e26011		31
1334	How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). <i>Blood</i> , 2013 , 121, 3085-94	2.2	60
1333	Role of the adaptor protein LNK in normal and malignant hematopoiesis. 2013 , 32, 3111-8		25
1332	Increased circulating IL-2R β (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study. 2013 , 27, 1430-3		11
1331	A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. 2013 , 54, 2322-4		13
1330	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 2013 , 27, 1874-81		389
1329	Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. 2013 , 27, 32-40		62
1328	High-risk acute myelogenous leukemia: treatment today ... and tomorrow. 2013 , 2013, 201-8		22
1327	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. 2013 , 98, 576-83		9
1326	Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. 2013 , 31, 2671-7		97
1325	The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. 2013 , 19, 327-35		35
1324	Absent or extremely low neutrophil alkaline phosphatase activity levels in patients with myelodysplastic syndromes. 2013 , 52, 479-82		1
1323	A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis. 2013 , 98, 1532-8		5
1322	Diagnosis and treatment of myelofibrosis: a personal perspective. 2013 , 10, 439-453		
1321	GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. <i>Blood</i> , 2013 , 122, 3908-17	2.2	115

1320	Effect of DLK1 on tumorigenesis in CD34CD38 bone marrow cells in myelodysplastic syndromes. 2013 , 6, 203-206		6
1319	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 2618-26	2.2	74
1318	GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. <i>Blood</i> , 2013 , 121, 5068-77	2.2	116
1317	Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. <i>Blood</i> , 2013 , 121, 2725-33	2.2	99
1316	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013 , 122, 1813-21	2.2	264
1315	Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. 2013 , 109, 878-84		68
1314	Acute myeloid leukemia with translocation t(3;5): new molecular insights. 2013 , 98, e52-4		9
1313	Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. 2013 , 98, e95-7		23
1312	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. 2013 , 98, 1414-20		37
1311	De Gruyter. 2013 , 21,		1
1310	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of hematologic oncology. 2013 , 2, 193-196		
1309	Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. 2013 , 98, 107-13		65
1308	Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?. 2013 , 98, 490-1		12
1307	Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. 2013 , 98, 568-75		52
1306	Novel therapies in the classicalBCRABL-negative myeloproliferative neoplasms. 2013 , 2, 137-150		
1305	The Spectrum of FIP1L1-PDGFR α -Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. 2013 , 92, e1-e9		62
1304	Stem cell transplantation in primary myelofibrosis of childhood. 2013 , 35, e120-2		7
1303	Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?. 2013 , 98, 10-22		20

1302	Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. 2013 , 98, e18-9	26
1301	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. 2013 , 98, 1421-3	10
1300	Involvement of TGF β 1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. 2013 , 98, 514-7	27
1299	The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features. 2013 , 11, 877-84; quiz 885	26
1298	Myelodysplastic syndromes: clinical practice guidelines in oncology. 2013 , 11, 838-74	72
1297	Imaging findings in recurrent extramedullary leukaemias. 2013 , 13, 26-35	7
1296	Case report: A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia. 2013 , 12, 5858-62	1
1295	Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia. 2013 , 13, 791-810	9
1294	Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. 2013 , 4, 111-21	12
1293	Acute colonic pseudo-obstruction following allogeneic stem cell transplantation successfully treated by neostigmine. 2013 , 48, 145-8	
1292	The myelodysplastic syndromes: diagnosis, prognosis and therapy. 2013 , 90-97	
1291	Indolent systemic mastocytosis limited to the bone: a case report and review of the literature. 2013 , 131, 198-204	2
1290	Utility of Multiplex Mutation Analysis in the Diagnosis of Chronic Myelomonocytic Leukemia. 2013 , 01,	
1289	Ruxolitinib for myelofibrosis. 2013 , 5, 927-931	1
1288	Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. 2013 , 48, 178-84	20
1287	Apoptosis deregulation in myeloproliferative neoplasms. 2013 , 11, 540-4	12
1286	Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rapidly Progressive and Fatal Disease without Aggressive Intervention. 2013 , 6, 201-4	5
1285	Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes. 2013 , 8, e57392	7

1284	The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFR β . 2013 , 8, e73059	9
1283	The molecular basis of acute myeloid leukemia. 751-768	
1282	Nöplasies lymphoödes et myeloödes. 2013 , 649-683	1
1281	Is CCDC26 a Novel Cancer-Associated Long-Chain Non-Coding RNA?. 2013 ,	
1280	Adrenal crisis in a patient with acute myeloid leukaemia. 2013 , 2013,	4
1279	Therapy-Related Acute Myeloid Leukemias. 2013 ,	1
1278	What should I know before ordering a bone marrow aspiration/biopsy in patients with vitamin B12 deficiency?. 2013 , 2013,	4
1277	B cells facilitate platelet production mediated by cytokines in patients with essential thrombocythaemia. 2014 , 112, 537-50	6
1276	Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload. 2014 , 49, 72-3	9
1275	Improved diagnosis of the transition to JAK2 (V617F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms. 2014 , 9, e86401	4
1274	Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death. 2014 , 9, e94374	40
1273	Antileukemic activity of sulforaphane in primary blasts from patients affected by myelo- and lympho-proliferative disorders and in hypoxic conditions. 2014 , 9, e101991	17
1272	ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML. 2014 , 9, e111568	8
1271	Nosocomial infection in adult admissions with hematological malignancies originating from different lineages: a prospective observational study. 2014 , 9, e113506	10
1270	Contribution of polymorphisms in IKZF1 gene to childhood acute leukemia: a meta-analysis of 33 case-control studies. 2014 , 9, e113748	14
1269	Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation. 2014 , 27, 299-304	1
1268	Polymorphism of XRCC1, XRCC3, and XPD genes and risk of chronic myeloid leukemia. 2014 , 2014, 213790	21
1267	Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms. 2014 , 2014, 485645	6

1266	MicroRNAs as Potential Biomarkers in Acute Promyelocytic Leukaemia. 2014 , 2014, 1-6	1
1265	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. 2014 , 7, 89-101	38
1264	Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. 2014 , 3, 1466-89	7
1263	MicroRNA dysregulation in the myelodysplastic syndromes. 2014 , 2, 174-86	2
1262	Cancer cytogenetics: methodology revisited. 2014 , 34, 413-25	30
1261	Diagnosis and subclassification of acute lymphoblastic leukemia. 2014 , 6, e2014073	84
1260	Isolated Myeloid Sarcoma of the Maxillary Sinus: A Case Report and Review of Literature. 2014 , 05,	2
1259	A novel melting curve-based method for detecting mutations in acute myeloid leukemia. 2014 , 8, 99-104	3
1258	A rare case of acute leukemic presentation of blastic plasmacytoid dendritic cell neoplasm without cutaneous lesions. 2014 , 34, 148-51	4
1257	Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. 2014 , 6, e2014020	8
1256	Prognostic Impact of Neuropilin-1 Expression in Egyptian Children with B-lineage Acute Lymphoblastic Leukemia. 2015 , 7, e2015009	1
1255	Pure erythroid leukemia in advanced breast cancer. 2014 , 49, 69-72	1
1254	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. 2014 , 49, 115-9	2
1253	. 2014 ,	7
1252	Pitfalls in the Diagnosis of Myelodysplastic Syndromes. 2014 , 97-105	
1251	Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. 2014 , 55, 1337-44	27
1250	Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis. 2014 , 89, 1157-8	2
1249	Stopping higher-risk myelodysplastic syndrome in its tracks. 2014 , 9, 421-31	2

1248	Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6)-methylguanine DNA methyltransferase expression. 2014 , 167, 664-70	13
1247	Novel methods and approaches to acute lymphoblastic leukemia drug discovery. 2014 , 9, 1435-46	7
1246	FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. 2014 , 41, 675-91	5
1245	Milestones in the curability of pediatric cancers. 2014 , 32, 2391-7	57
1244	A novel insertion ins(18;5)(q21.1;q31.2q35.1) in acute myeloid leukemia associated with microdeletions at 5q31.2, 5q35.1q35.2 and 18q12.3q21.1 detected by oligobased array comparative genomic hybridization. 2014 , 7, 63	3
1243	Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. 2014 , 32, e76-9	16
1242	Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?. 2014 , 55, 2706-11	4
1241	Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. 2014 , 28, 2355-66	19
1240	Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. 2014 , 27, 814-22	30
1239	Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. 2014 , 4, e170	74
1238	Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemia. 2014 , 2, 265-70	
1237	Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. 2014 , 9, 1108-19	61
1236	Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. 2014 , 27, 681-9	31
1235	Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Franaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). 2014 , 49, 756-60	27
1234	High proportion of CD34+/CD38-cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia. 2014 , 55, 611-7	9
1233	Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. 2014 , 49, 679-83	58
1232	A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases. 2014 , 10, 1679-88	6
1231	Priapism as the initial symptom of primary penile lymphoma: A case report. 2014 , 8, 1929-1932	11

1230	Daunorubicin for the treatment of acute myeloid leukemia. 2014 , 2, 1075-1087	
1229	Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. 2014 , 7, 255-64	12
1228	Isolated gastric myeloid sarcoma: a case report and review of the literature. 2014 , 2014, 541807	9
1227	Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. 2014 , 99, e8-10	11
1226	Acute basophilic leukemia presenting with maculopapular rashes and a gastric ulcer: A case report. 2014 , 8, 2513-2516	2
1225	Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid. 2014 , 142, 546-52	11
1224	Established and novel agents for myelodysplastic syndromes. 2014 , 2014, 82-9	6
1223	Allergic diseases and risk of hematopoietic malignancies in a cohort of postmenopausal women: a report from the Iowa Women's Health Study. 2014 , 23, 1903-12	9
1222	[Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms]. 2014 , 155, 2074-81	1
1221	Overexpression of SLC25A38 protein on acute lymphoblastic leukemia cells. 2014 , 7, 1422-1426	4
1220	Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia. 2014 , 15, 1927-45	18
1219	Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. 2015 , 6, 1-16	12
1218	Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. 2014 , 20, 2226-35	56
1217	BCL6 corepressor gene dysregulation due to chromosomal translocation in acute myeloid leukemia: a new mechanism based on long non-coding RNA dislocation?. 2014 , 55, 2199-201	2
1216	A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms. 2014 , 2014, 458457	5
1215	Optimizing the management of patients with myelofibrosis. 2014 , 18, 330-7	1
1214	The Frequency Of JAK2 V617F Gen Mutation And Its Associations With Whole Blood Count Parameters. 2014 , 39, 93-98	2
1213	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. 2014 , 99, 865-72	56

1212	Glutathione S-transferase P1 promoter hypermethylation in acute myeloid leukemia: association with A111G germline polymorphism and chromosomal abnormalities. 2014 , 55, 2637-9	
1211	Myeloid neoplasms with der(1)t(1;19) may constitute a specific entity characterized by a cytogenetic biomarker and gene mutations involved in DNA methylation. 2014 , 55, 2652-5	1
1210	Raman spectroscopy for the assessment of acute myeloid leukemia: a proof of concept study. 2014 ,	0
1209	Extramedullary acute leukemia developing in a pre-existing osteoma cutis. 2014 , 41, 606-11	2
1208	Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis. 2014 , 89, 1043-6	8
1207	Association of XRCC3 Thr241Met polymorphism and leukemia risk: evidence from a meta-analysis. 2014 , 55, 2130-4	7
1206	Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. 2014 , 166, 720-8	6
1205	DNMT3A: the DioNysian MonsTer of acute myeloid leukaemia. 2014 , 5, 187-96	8
1204	Mutations in the RNA splicing machinery genes in myelofibrotic transformation of essential thrombocythaemia and polycythaemia vera. 2014 , 164, 605-7	3
1203	A novel multiplex rt-PCR assay for the detection of four chromosomal translocations of leukemia. 2014 , 18, 810-9	5
1202	Immune thrombocytopenia in chronic myelomonocytic leukemia. 2014 , 93, 521-6	24
1201	Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). 2014 , 92, 527-36	76
1200	Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. 2014 , 166, 902-10	15
1199	Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. 2014 , 89, 168-73	21
1198	IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. 2014 , 89, E142-9	14
1197	CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. 2014 , 86, 340-9	7
1196	Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review. 2014 , 93, 247-59	24
1195	LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype. 2014 , 64, 226-33	8

1194	Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients. 2014 , 89, 295-301	12
1193	Development and validation of risk models and molecular diagnostics to permit personalized management of cancer. 2014 , 120, 11-9	9
1192	SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. 2014 , 167, 233-7	31
1191	Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients. 2014 , 86, 32-43	10
1190	Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. 2014 , 89, 509-16	22
1189	Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. 2014 , 93, 54-62	7
1188	Haematopoietic development and leukaemia in Down syndrome. 2014 , 167, 587-99	71
1187	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. 2014 , 120, 1838-46	107
1186	Clinical potential of elacytarabine in patients with acute myeloid leukemia. 2014 , 5, 211-20	7
1185	CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm. 2014 , 53, 78-89	25
1184	Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. 2014 , 93, 429-38	23
1183	Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1. 2014 , 165, 734-7	3
1182	Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. 2014 , 93, 81-5	38
1181	Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. 2014 , 93, 103-11	11
1180	Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. 2014 , 9, 350-9	6
1179	Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes. 2014 , 14, 111	6
1178	Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. 2014 , 48, 230-8	11
1177	Clinical characteristics and prognosis of nonleukemic myeloid sarcoma. 2014 , 347, 434-8	11

1176	The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes. 2014 , 55, 1538-43		17
1175	Advances in treatment of de-novo pediatric acute myeloid leukemia. 2014 , 26, 656-62		12
1174	Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome. 2014 , 20, 340-6		9
1173	A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic VβVα T cells. 2014 , 37, 321-30		16
1172	Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromes. 2014 , 106, dju025		2
1171	A Preliminary Study of the Suitability of Archival Bone Marrow and Peripheral Blood Smears for Diagnosis of CML Using FISH. 2014 , 2014, 604165		2
1170	Development of bead-based suspension array technology for the diagnosis of thalassemia. 2014 , 89, 1158-9		4
1169	Myelodysplastic syndromes in the United States: an update for clinicians. 2014 , 46, 283-9		19
1168	Contraception for the Medically Challenging Patient. 2014 ,		2
1167	Clinical Ophthalmic Oncology. 2014 ,		2
1166	Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. <i>Blood</i> , 2014 , 123, 3943-50	2.2	31
1165	Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. 2014 , 18, 1237-51		17
1164	The epigenetic landscape of acute myeloid leukemia. 2014 , 2014, 103175		61
1163	Myeloid sarcoma: a rare case of an orbital mass mimicking orbital pseudotumor requiring neurosurgical intervention. 2014 , 2014, 395196		7
1162	Complex variant of Philadelphia translocation involving chromosomes 9, 12, and 22 in a case with chronic myeloid leukaemia. 2014 , 2014, 691630		
1161	Dysplasia features of myelodysplastic syndrome in ethnically Chinese people. 2014 , 131, 126-32		4
1160	Unusual intracytoplasmic crystalline inclusions in chronic myelomonocytic leukemia with double minute chromosomes and MYC amplification: a rare case. 2014 , 132, 68-72		3
1159	Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool. 2014 , 5, e0025		

1158	A Case of Acute Myeloid Leukemia (FAB M2) with Inversion 16 Who Presented with Pelvic Myeloid Sarcoma. 2014 , 2014, 246169	2
1157	Extramedullary myeloid tumor involving the pancreas: a case report and review of the literature. 2014 , 31, 295-300	1
1156	Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. 2014 , 106, djt462	17
1155	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. 2014 , 32, 2691-8	295
1154	Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital. 2014 , 132, 144-51	9
1153	Genomic characterization of acute leukemias. 2014 , 23, 487-506	20
1152	Cryptic chromosome abnormalities in a patient with mixed phenotype acute leukemia. 2014 , 55, 680-2	1
1151	Disseminated noninterstitial granulomatous dermatitis as a cutaneous manifestation of the preleukemic state in a patient with myelodysplasia and ulcerative colitis--apropos a case and review of the literature. 2014 , 36, e117-20	6
1150	Selected parameters of hemostasis in patients with myeloproliferative neoplasms. 2014 , 25, 464-70	3
1149	The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy. 2014 , 21, 148-54	7
1148	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 2014 , 167, 541-6	29
1147	Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. 2014 , 12, 1324-9	61
1146	Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. 2014 , 8, 221-31	24
1145	T-cell/myeloid mixed-phenotype acute leukemia with monocytic differentiation and isolated 17p deletion. 2014 , 36, 293-6	2
1144	NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. 2014 , 42, 101-13.e5	23
1143	Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms. 2014 , 50, 418-24	8
1142	Hypereosinophilic syndrome. 2014 , 112, 484-8	22
1141	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. 2014 , 38, 29-33	15

1140	Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. 2014 , 38, 744-50	35
1139	JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis. 2014 , 30, 4-8	0
1138	Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients. 2014 , 93, 705-7	2
1137	Prevalence of JAK2 V617F mutation in west algerian population with chronic myeloproliferative neoplasms: A multicenter study. 2014 , 6, 138-144	
1136	Intact expression status of RASSF1A in acute myeloid leukemia. 2014 , 31, 770	8
1135	Response to corticosteroids and cytotoxic drugs in a case of idiopathic hypereosinophilic syndrome with predominantly elevated eosinophils and multiple clinical manifestations. 2014 , 30, 162-5	
1134	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. 2014 , 89, 610-5	19
1133	Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. 2014 , 28, 1568-70	118
1132	Pediatric Hematology-Oncology in Countries with Limited Resources. 2014 ,	6
1131	Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia. 2014 , 164, 384-95	41
1130	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. 2014 , 89, 604-9	32
1129	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. 2014 , 28, 1494-500	211
1128	The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFR β and PDGFR β D842V. 2014 , 8, 728-40	15
1127	Marked and persistent eosinophilia in the absence of clinical manifestations. 2014 , 133, 1195-202	40
1126	Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a meta-analysis. 2014 , 35, 2191-7	12
1125	Development of treatment and clinical results in childhood AML in Austria (1993-2013). 2014 , 7, 63-74	2
1124	Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. 2014 , 31, 869	24
1123	Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels. 2014 , 93, 1149-57	21

1122	Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis. 2014 , 35, 615-21		8
1121	Myelodysplastic syndromes. 2014 , 383, 2239-52		264
1120	Guidelines for the diagnosis and management of adult myelodysplastic syndromes. 2014 , 164, 503-25		69
1119	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. 2014 , 38, 551-6		8
1118	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2014 , 123, 2645-51	2.2	145
1117	Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. 2014 , 14, 163-71		8
1116	Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. 2014 , 89, 97-108		96
1115	CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. 2014 ,		14
1114	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. 2014 , 89, E121-4		145
1113	Calreticulin mutations and long-term survival in essential thrombocythemia. 2014 , 28, 2300-3		79
1112	How common are myeloproliferative neoplasms? A systematic review and meta-analysis. 2014 , 89, 581-7		97
1111	Masked polycythemia vera (mPV): results of an international study. 2014 , 89, 52-4		103
1110	Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management. 2014 , 89, 651-8		16
1109	Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. 2014 , 28, 958-61		50
1108	Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients. 2014 , 38, 722-5		3
1107	Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. 2014 , 120, 1686-94		33
1106	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. 2014 , 28, 823-9		110
1105	An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. 2014 , 28, 1407-13		167

1104	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. <i>Blood</i> , 2014 , 123, 2220-8	2.2	412
1103	Neurologic aspects of lymphoma and leukemias. 2014 , 120, 1027-43		4
1102	Chronic myeloproliferative diseases. 2014 , 120, 1073-81		8
1101	CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. 2014 , 28, 1472-7		381
1100	Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. 2014 , 28, 1001-7		26
1099	Non-coding RNAs and Cancer. 2014 ,		6
1098	Outcome of acute myeloid leukemia and high-risk myelodysplastic syndrome according to health insurance status. 2014 , 14, 509-13		2
1097	Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. 2014 , 50, 3198-205		24
1096	Concise review: Leukemia stem cells in personalized medicine. 2014 , 32, 844-51		40
1095	A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. <i>Blood</i> , 2014 , 124, 1645-54	2.2	153
1094	Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein. 2014 , 28, 961-4		10
1093	Myelodysplastic Syndromes. 2014 , 181-284		
1092	Acute Myeloid Leukaemia. 2014 , 285-421		1
1091	Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. <i>Blood</i> , 2014 , 123, 2066-74	2.2	33
1090	Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group. 2014 , 167, 80-6		15
1089	Mast cell leukemia: an extremely rare disease. 2014 , 77, 446-9		4
1088	First case report of acute myeloid sarcoma post renal transplant. 2014 , 46, 2411-3		4
1087	Fanconi anemia and the development of leukemia. 2014 , 27, 214-21		124

1086	Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. 2014 , 20, 1566-72	18
1085	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 2014 , 28, 1804-10	213
1084	Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. 2014 , 289, 20543-58	37
1083	Clinical and genetic predictors of prognosis in myelodysplastic syndromes. 2014 , 99, 956-64	71
1082	Clinical significance of microcytosis in patients with primary myelofibrosis. 2014 , 38, 1212-6	6
1081	Mechanistic aspects of lauryl gallate-induced differentiation and apoptosis in human acute myeloid leukemia cells. 2014 , 71, 197-206	8
1080	The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. 2014 , 28, 1242-51	30
1079	Acute leukemia. 2014 , 32, 579-96	19
1078	Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice. 2014 , 9, 301-10	2
1077	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. 2014 , 28, 1586-95	161
1076	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2014 , 25 Suppl 3, iii57-69	58
1075	Alcohol drinking and risk of leukemia-a systematic review and meta-analysis of the dose-risk relation. 2014 , 38, 339-45	18
1074	Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome. 2014 , 3, 1188-98	7
1073	I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. 2014 , 9, 400-6	5
1072	Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort. 2014 , 3, 22	5
1071	Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. 2014 , 32, 1396-409	31
1070	Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. 2014 , 49, 1029-35	27
1069	Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. 2014 , 89, 915-25	72

1068	WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. 2014 , 166, 911-9	45
1067	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. 2014 , 32, 1242-8	187
1066	Interferon β gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. 2014 , 38, 1177-83	21
1065	Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. 2014 , 93, 1467-72	4
1064	Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. 2014 , 93, 1279-86	65
1063	Myelodysplastische Syndrome. 2014 , 20, 689-700	
1062	Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. 2014 , 166, 189-201	12
1061	Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. 2014 , 111, 874-82	45
1060	Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia. 2014 , 33, 44	11
1059	Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells. 2014 , 219, 28-36	12
1058	Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. 2014 , 4, e218	183
1057	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. <i>Blood</i> , 2014 , 124, 1445-9	2.2 93
1056	Is targeted therapy feasible in acute myelogenous leukemia?. 2014 , 9, 118-27	8
1055	The use of molecular genetics to refine prognosis in acute myeloid leukemia. 2014 , 9, 148-57	9
1054	Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis. 2014 , 99, 154-61	24
1053	Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases. 2014 , 99, 721-5	8
1052	Increased CD34+CD38 ⁻ CD123 ⁺ cells in myelodysplastic syndrome displaying malignant features similar to those in AML. 2014 , 100, 60-9	29
1051	A Case of AML-M2 with Sole Interstitial Deletion in 9q Without AML1-ETO/Inv 16 Rearrangement and FLT3/NPM1 Mutations. 2014 , 30, 186-9	1

1050	Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. 2014 , 13, 123	35
1049	Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis. 2014 , 38, 1207-11	5
1048	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. 2014 , 89, 306-9	39
1047	Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age. 2014 , 167, 162-76	11
1046	[Lineage assignment in acute leukemia: confrontation between cytology and immunophenotyping]. 2014 , 62, 345-7	2
1045	MST1/2 and YAP1 gene expression in acute myeloid leukemia. 2014 , 55, 2189-91	8
1044	[Radiation therapy of sinonasal natural killer/T-cell lymphoma]. 2014 , 18, 147-53; quiz 161, 163	0
1043	Therapy-related AML: a slip of the lip can sink a ship. 2014 , 38, 418-20	10
1042	Le polynucléaire éosinophile : nouveautés en physiologie et implications diagnostiques. 2014 , 2014, 73-85	
1041	Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. 2014 , 38, 490-5	27
1040	Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. 2014 , 133, 303-5	23
1039	Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. 2014 , 210, 369-76	10
1038	The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. 2014 , 75, 113-8	21
1037	High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. 2014 , 38, 71-5	25
1036	The multidrug resistance pumps are inhibited by silibinin and apoptosis induced in K562 and KCL22 leukemia cell lines. 2014 , 38, 575-80	9
1035	Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. 2014 , 38, 91-4	3
1034	Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. 2014 , 14, e115-8	15
1033	Automated analysis of bone marrow aspirates from dogs with haematological disorders. 2014 , 151, 67-79	5

1032	Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. 2014 , 111, 8589-94	40
1031	Repetitive genomic elements and overall DNA methylation changes in acute myeloid and childhood B-cell lymphoblastic leukemia patients. 2014 , 100, 79-87	15
1030	Lenalidomide for patients with red blood cell transfusion-dependent IPSS low- or intermediate-1-risk myelodysplastic syndromes. 2014 ,	
1029	Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. 2014 , 58, 2775-80	32
1028	Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. 2014 , 58, 865-73	37
1027	Elevated TIM3+ hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis. 2014 , 38, 714-21	15
1026	Toll-like receptors in lymphoid malignancies: double-edged sword. 2014 , 89, 262-83	17
1025	XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia. 2014 , 55, 365-70	17
1024	Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. 2014 , 99, 54-9	39
1023	Changing histopathological diagnostics by genome-based tumor classification. 2014 , 5, 444-59	12
1022	Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature. 2014 , 2014,	7
1021	Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma. 2014 , 2014,	2
1020	De Gruyter. 2014 , 22,	4
1019	Eosinophilic cystitis in a patient with hypereosinophilia syndrome: A case report. 2014 , 8, 49-51	3
1018	Multiple Myeloma and Evolution of Novel Biomarkers and Therapies. 2014 , 895-934	
1017	Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma. 2014 , 935-952	
1016	Recent developments in myelodysplastic syndromes. <i>Blood</i> , 2014 , 124, 2793-803	2.2 116
1015	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014 , 124, 2507-13; quiz 2615	2.2 424

1014	How we treat higher-risk myelodysplastic syndromes. <i>Blood</i> , 2014 , 123, 829-36	2.2	80
1013	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. <i>Blood</i> , 2014 , 124, e21-32	2.2	89
1012	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. <i>Blood</i> , 2014 , 124, 1513-21	2.2	195
1011	PDGFRB disease: right diagnosis to prolong survival. <i>Blood</i> , 2014 , 123, 3526-8	2.2	1
1010	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014 , 124, 3021-3	2.2	80
1009	Life, genes, and death in Ph- MPNs. <i>Blood</i> , 2014 , 124, 2471-2	2.2	1
1008	Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2014 , 124, 3932-8	2.2	53
1007	Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. 2014 , 99, 37-45		34
1006	Reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome. 2014 , 7, 188-94		1
1005	Pathology quiz case: Plasmacytoid dendritic cell neoplasm. 2014 , 5, 50-2		3
1004	Outcomes in patients with mixed phenotype acute leukemia in Morocco. 2014 , 36, e392-7		9
1003	Lateral skull base destruction: unusual clinical progress of lymphoma. 2014 , 25, e373-5		1
1002	Calreticulin mutations in Chinese with primary myelofibrosis. 2014 , 99, 1697-700		33
1001	Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. 2014 , 93, 1-10		37
1000	Association between traumatic lumbar puncture and the risk of central nervous system relapse in adults with acute lymphoblastic leukaemia. 2015 , 78, 124-128		0
999	Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature. 2015 , 10, 3261-3265		5
998	Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?. 2015 , 2015, 308-16		14
997	Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?. 2015 , 2015, 349-54		9

996	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. 2015 , 100, e434-7	18
995	A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. 2015 , 5, 12	12
994	Management of symptoms in polycythemia vera and essential thrombocythemia patients. 2015 , 2015, 340-8	10
993	Molecularly targeted therapies for acute myeloid leukemia. 2015 , 2015, 579-83	19
992	Characterization and targeting of neoplastic stem cells in Ph+chronic myeloid leukemia. 2015 , 4, 151-165	1
991	The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes. 2015 , 100, 633-42	20
990	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. 2015 , 90, 276-81	114
989	Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. 2015 , 170, 487-95	35
988	A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. 2015 , 3, 448-52	2
987	Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. 2015 , 171, 478-90	23
986	Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. 2015 , 100, 42-8	81
985	Laboratory Diagnosis of Haematological Neoplasms. 2015 , 332-351	
984	Adult Acute Lymphoblastic Leukaemia. 2015 , 371-383	
983	Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. 2015 , 5, e369	123
982	Differenzialdiagnose BCR-ABL1-negativer myeloproliferativer Neoplasien. 2015 , 39,	
981	Association of ßup-like blasts morphology with NPM1 mutation in acute myeloid leukemia. 2015 , 23,	
980	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015 , 125, 499-503	2.2 90
979	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. <i>Blood</i> , 2015 , 125, 133-9	2.2 64

978	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015 , 125, 1857-65	2.2	118
977	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , 2015 , 125, 1367-76	2.2	497
976	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015 , 126, 1575-84	2.2	46
975	Splicing up the classification of myelodysplasia. <i>Blood</i> , 2015 , 126, 128-9	2.2	1
974	MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. <i>Blood</i> , 2015 , 126, 2355-61	2.2	214
973	The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons. 2015 , 54, 445-51		5
972	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. 2015 , 100, e409-11		9
971	Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia. 2015 , 10, 103-110		15
970	Pediatric AML: From Biology to Clinical Management. 2015 , 4, 127-49		88
969	CD133 marks a stem cell population that drives human primary myelofibrosis. 2015 , 100, 768-79		10
968	Response to comments from Drs. Alter and Rosenberg. 2015 , 100, e381-2		
967	Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia. 2015 , 5, 25		1
966	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. 2015 , 121, 3577-90		41
965	Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. 2015 , 90, n/a-n/a		
964	CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8; 21). 2015 , 170, 391-7		14
963	Downregulated Poly-C binding protein-1 is a novel predictor associated with poor prognosis in Acute Myeloid Leukemia. 2015 , 10, 147		13
962	Acute basophilic leukaemia in a three-month-old calf. 2015 , 57, 48		6
961	Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. 2015 , 8, 68		5

960	Increased bone marrow uptake of 18F-FDG in leukemia patients: preliminary findings. 2015 , 4, 521	19
959	Refractory myeloid sarcoma with a FIP1L1-PDGFR α rearrangement detected by clinical high throughput somatic sequencing. 2015 , 4, 30	2
958	Paediatric acute myeloid leukaemia with the t(7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspects. 2015 , 3, 21	14
957	WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience. 2015 , 123, 787-92	4
956	Circulating microRNA as Biomarkers in Hematological Malignancies. 2015 , 106, 123-138	4
955	JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients. 2015 , 37, 654-60	7
954	Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. 2015 , 44, 79-93	27
953	Nonbiological factors affecting survival in younger patients with acute myeloid leukemia. 2015 , 121, 3877-84	35
952	The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. 2015 , 170, 236-46	28
951	The Corepressor Rcor1 Is Essential for Normal Myeloerythroid Lineage Differentiation. 2015 , 33, 3304-14	8
950	Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. 2015 , CD010248	7
949	Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. 2015 , 90, 831-41	80
948	The applicability of the WHO classification in paediatric AML. A NOPHO-AML study. 2015 , 169, 859-67	13
947	Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. 2015 , 170, 372-83	47
946	Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?. 2015 , 37, 723-8	3
945	Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. 2015 , 13, 1226-37	32
944	Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. 2015 , 35, 2042-9	29
943	Leukemia blast cell identification. 2015 , 5, 74-85	

942	Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India. 2015 , 11, 242-52	18
941	The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. 2015 , CD010432	22
940	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. 2015 , 90, 790-5	160
939	Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. 2015 , 90, 1116-21	10
938	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. 2015 , 137, 2083-92	14
937	De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology. 2015 , 23, 733-9	
936	7. Hämatologische Diagnostik.	
935	Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. 2015 , 48, 583-7	2
934	Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes. 2015 , 15, 148-61	1
933	The Evolution of Genetics Techniques for Leukemia Diagnosis. 2015 , 03,	
932	Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest. 2015 , 2015, 670580	38
931	The Impact of Molecular Genetic in Acute Myeloid Leukemias. 2015 , 06,	
930	Calreticulin and JAK2V617F Mutations in Essential Thrombocythemia and Their Potential Role in Diagnosis and Prognosis. 2015 , 01,	1
929	Importance of classical morphology in the diagnosis of myelodysplastic syndrome. 2015 , 7, e2015035	14
928	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. 2015 , 9, 2687-94	3
927	Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. 2015 , 2015, 415024	43
926	Role of heme oxygenase-1 in demethylating effects on SKM-1 cells induced by decitabine. 2015 , 14, 17788-98	1
925	Chronic neutrophilic leukemia: a clinical perspective. 2015 , 8, 2383-90	5

924	Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. 2015 , 50, 204-17	29
923	An unexpected complication of chronic myelomonocytic leukemia: severe renal failure due to malignant tubulo-interstitial cell infiltration. 2016 , 9, 1-4	4
922	Systemic mastocytosis: a rare cause of single vertebral body uptake on bone scan. 2015 , 9, 31-41	1
921	Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm. 2015 , 35, 348-51	0
920	Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis. 2015 , 7, 2459-65	0
919	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation. 2015 , e398-412	8
918	Routine Cytogenetic Analysis of Chromosome Abnormalities in Acute Lymphoblastic Leukemia. 2015 , 6, 612	
917	Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients. 2015 , 6, 977-90	13
916	The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms. 2015 , 12, 2465-85	5
915	A neonate with a vesiculopustular rash. 2015 , 44, e1-5	2
914	Construction of gene/protein interaction networks for primary myelofibrosis and KEGG pathway-enrichment analysis of molecular compounds. 2015 , 14, 16126-32	1
913	Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. 2015 , 10, e0126555	18
912	The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. 2015 , 10, e0135945	35
911	Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients. 2016 , 17, 52-70	20
910	Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia. 2015 , 2015, 757694	14
909	Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics. 2015 , 2015, 384575	2
908	A Case Report on the Progression of Myeloid Sarcoma to Form Multiple Metastatic Deposits without Developing Acute Myeloid Leukaemia. 2015 , 2015, 162154	2
907	Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups. 2015 , 2015, 209745	4

906	Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy. 2015 , 2015, 253294	9
905	Promyelocytic Leukemia with No Retinoic Acid Receptor Alpha Abnormality but with RUNX1T1 Insertion to Chromosome 7q: A Classification and Management Dilemma. 2015 , 2015, 412016	2
904	Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome. 2015 , 2015, 872983	2
903	Pediatric Acute Lymphoblastic Leukemia: From Diagnosis to Prognosis. 2015 , 44, e168-74	2
902	The Hematopoietic Niche in Myeloproliferative Neoplasms. 2015 , 2015, 347270	14
901	Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL)). 2015 ,	1
900	Hematopoietic cell transplantation for myelodysplastic syndrome. 2015 , e375-80	6
899	Myeloproliferative disorders apart from chronic myeloid leukemias. 2015 , 21, 348-356	
898	Recent Advances in the 5q- Syndrome. 2015 , 7, e2015037	20
897	Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis: an observational study with a systematic review of the literature. 2015 , 27, 77-83	10
896	Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). 2015 , 29, 1502-13	76
895	Evaluation of the association between the JAK2 46/1 haplotype and myeloproliferative neoplasm in a Korean population. 2015 , 37, e91-5	3
894	Étude des manifestations hématoLOGIQUES dans une série de 133 patients avec une maladie d'Erdheim-Chester met en évidence une association aux pathologies myéLOïdes chez 9 patients. 2015 , 36, A39-A40	
893	The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy. 2015 , 102, 35-40	4
892	CD79a, CD56 ve CD5 ko-ekspresyonu gsteren ve bifenotipik lemi ile karn AML M10 bcuk olgu. 2015 , 42,	
891	Discrimination and classification of acute lymphoblastic leukemia cells by Raman spectroscopy. 2015 ,	1
890	CEBPA methylation and mutation in myelodysplastic syndrome. 2015 , 32, 192	24
889	miR-155 regulative network in FLT3 mutated acute myeloid leukemia. 2015 , 39, 883-96	15

888	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. 2015 , 90, 411-6	45
887	Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. 2015 , 90, 483-6	19
886	Ruxolitinib for the treatment of patients with polycythemia vera. 2015 , 8, 391-401	6
885	Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil. 2015 , 70, 322-5	6
884	Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. 2015 , 56, 2536-42	12
883	Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. 2015 , 6, 103-19	35
882	Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients. 2015 , 66, 756-67	47
881	Survival of patients with mixed phenotype acute leukemias: A large population-based study. 2015 , 39, 606-16	34
880	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. 2015 , 19, 1187-202	11
879	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. 2015 , 90, 288-94	38
878	Neonatal acute megakaryoblastic leukemia mimicking congenital neuroblastoma. 2015 , 3, 145-9	6
877	Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. 2015 , 20, 1154-60	11
876	Circulating microRNAs in Disease Diagnostics and their Potential Biological Relevance. 2015 ,	7
875	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. 2015 , 100, 1139-45	151
874	Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases. 2015 , 9, 468-77	2
873	Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. 2015 , 39, 835-9	4
872	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. 2015 , 100, 927-34	74
871	Ruxolitinib for treatment of polycythemia vera. 2015 , 3, 1085-1096	0

870	Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. 2015 , 10, 413-20	18
869	Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data. 2015 , 39, 892-900	20
868	Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance. 2015 , 275-317	2
867	Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia. 2015 , 43, 869-879.e22	3
866	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. 2015 , 21, 2106-2114	44
865	Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. 2015 , 33, 340-8	67
864	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. 2015 , 39, 52-7	16
863	More is better: combination therapies for myelodysplastic syndromes. 2015 , 28, 22-31	17
862	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. 2015 , 8, 43-56	21
861	Myeloid sarcoma of the rib: An atypical isolated chest finding. 2015 , 46, 105-109	1
860	Gastrointestinal manifestations of systemic disease: a multimodality review. 2015 , 40, 1926-43	15
859	Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression. 2015 , 39, 138-43	25
858	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. 2015 , 90, E80-5	59
857	Spontaneous remission of acute myeloid leukemia. 2015 , 56, 1727-34	18
856	Blood dyscrasias. 2015 , 171-192	
855	Transplant for MDS: challenges and emerging strategies. 2015 , 28, 43-54	3
854	Mitochondrial dependency in progression of acute myeloid leukemia. 2015 , 21, 41-8	32
853	Breakpoint heterogeneity in (2;3)(p15-23;q26) translocations involving EVI1 in myeloid hemopathies. 2015 , 54, 160-3	9

852	Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná 2015 , 37, 21-7	16
851	Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?. 2015 , 50, 628-36	6
850	Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. 2015 , 29, 1243-52	26
849	Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. 2015 , 53, 1005-11	6
848	Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. 2015 , 56, 1246-51	4
847	A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. 2015 , 169, 71-6	26
846	Secondary acute myeloid leukemia arising early after cyclophosphamide treatment. 2015 , 37, 289-91	4
845	Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children. 2015 , 174, 525-31	11
844	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. 2015 , 21, 373-8	17
843	Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. 2015 , 15, 236-44	19
842	Tea consumption reduces the risk of de novo myelodysplastic syndromes. 2015 , 39, 164-9	8
841	Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. 2015 , 15, e39-41	6
840	Rates of complete diagnostic testing for patients with acute myeloid leukemia. 2015 , 4, 519-22	6
839	Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. 2015 , 5, e275	35
838	Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. 2015 , 21, 342-9	16
837	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. 2015 , 90, 162-73	166
836	Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML). 2015 , 29, 500-2	9
835	A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis. 2015 , 101, 295-304	8

834	Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. 2015 , 64, 237-47	29
833	ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features. 2015 , 37, 287-303	83
832	Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome. 2015 , 39, 424-8	8
831	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. 2015 , 100, 400-8	41
830	Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. 2015 , 15, 358-363	37
829	The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features. 2015 , 94, 35-43	13
828	Clonal origin and evolution of myelodysplastic syndrome analyzed by dysplastic morphology and fluorescence in situ hybridization. 2015 , 101, 58-66	1
827	WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients. 2015 , 94, 761-9	1
826	Therapy-related myelodysplastic syndrome. 2015 , 14, 655-65	5
825	Myeloid Proliferations Associated with Down Syndrome. 2015 , 8, 169-176	5
824	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. 2015 , 56, 2793-802	24
823	Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations. 2015 , 144, 19-28	6
822	Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?. 2015 , 10, 282-91	30
821	IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort. 2015 , 15, e101-4	2
820	Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. 2015 , 56, 1698-703	46
819	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. 2015 , 2, e260-6	21
818	Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. 2015 , 39, 242-9	9
817	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. 2015 , 16, 1025-1036	113

816	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. 2015 , 20, 1069-76	18
815	BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR. 2015 , 467, 357-63	22
814	MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. 2015 , 32, 206	13
813	Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. 2015 , 100, e226-8	33
812	Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome. 2015 , 16, 966-89	17
811	Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. 2015 , 9, 1217-1220	3
810	Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: evidence from four decades of US population data. 2015 , 39, 720-6	18
809	Protein kinase Ce inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients. 2015 , 29, 2192-201	13
808	HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. 2015 , 29, 1496-501	36
807	Clinical features and survival of asian pediatric patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. 2015 , 134, 1-6	5
806	High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia. 2015 , 36, 9711-6	13
805	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. 2015 , 39, 950-6	56
804	Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. 2015 , 5, e286	4
803	Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents. 2015 , 56, 3267-9	3
802	Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities. 2015 , 144, 44-60	32
801	Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota. 2015 , 94, 1667-75	7
800	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. 2015 , 21, 1425-30	9
799	Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia. 2015 , 15, 477-83	15

798	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. 2015 , 29, 741-4		33
797	RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. 2015 , 16, 877-90		35
796	Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?. 2015 , 52, 223-31		7
795	Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research. <i>Blood</i> , 2015 , 126, 1057-68	2.2	36
794	Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms. 2015 , 9, 735-738		9
793	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. <i>Blood</i> , 2015 , 125, 3618-26	2.2	146
792	Insights into cell ontogeny, age, and acute myeloid leukemia. 2015 , 43, 745-55		19
791	Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. 2015 , 50, 1180-6		13
790	The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. 2015 , 144, 165-71		31
789	Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia. 2015 , 20, 187-95		33
788	Myelofibrosis patients in Belgium: disease characteristics. 2015 , 70, 105-11		7
787	Neutrophilic progression in a case of polycythemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization. 2015 , 211, 341-3		4
786	ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate. 2015 , 36, 7599-606		8
785	Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. 2015 , 15, 253-61		13
784	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. 2015 , 100, 780-5		34
783	Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience. 2015 , 56, 3129-34		1
782	Erythropoietin receptor mutation--a rush of blood to the head?. 2015 , 94, 1229-31		1
781	Single TCR-V α evaluation discloses the circulating T cell clone in Sezary syndrome: one family fits all!. 2015 , 307, 487-93		4

780	AML versus ICU: outcome of septic AML patients in an intensive care setting. 2015 , 141, 1645-51		6
779	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. 2015 , 127, 12-5		1
778	The ⁵⁷ Fe hyperfine interactions in iron storage proteins in liver and spleen tissues from normal human and two patients with mantle cell lymphoma and acute myeloid leukemia: a Mössbauer effect study. 2015 , 230, 123-130		6
777	Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies. 2015 , 10, 112-7		13
776	Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. 2015 , 39, 222-8		12
775	Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML. <i>Blood</i> , 2015 , 125, 2815-24	2.2	37
774	Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. 2015 , 11, 719-33		37
773	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015 , 125, 3236-45		90
772	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. <i>Blood</i> , 2015 , 126, 233-41	2.2	269
771	Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. 2015 , 141, 2131-8		34
770	Cyclosporine Combined with Levamisole for Lower-Risk Myelodysplastic Syndromes. 2015 , 134, 138-45		5
769	Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission. 2015 , 50, 907-13		20
768	Annotation of Sequence Variants in Cancer Samples: Processes and Pitfalls for Routine Assays in the Clinical Laboratory. 2015 , 17, 339-51		7
767	EPMA position paper in cancer: current overview and future perspectives. 2015 , 6, 9		60
766	Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy. 2015 , 95, 480-3		2
765	Chronic myelomonocytic leukemia: Forefront of the field in 2015. 2015 , 95, 222-42		19
764	Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. 2015 , 33, 1839-49		11
763	T-cell acute lymphoid leukemia resembling Burkitt leukemia cell morphology: A case report. 2015 , 9, 1236-1238		3

762	Whole genome and transcriptome analysis of a novel AML cell line with a normal karyotype. 2015 , 39, 709-18		4
761	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015 , 126, 9-16	2.2	1005
760	Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. 2015 , 15, 443-9		28
759	Expression profiling of cancer-related galectins in acute myeloid leukemia. 2015 , 36, 7929-39		11
758	Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis. 2015 , 141, 1859-70		17
757	Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. 2015 , 22, 171-6		15
756	Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. 2015 , 22, 163-70		21
755	Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. 2015 , 94, 1127-38		168
754	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. 2015 , 29, 1344-9		48
753	Current and future treatment options for polycythemia vera. 2015 , 94, 901-10		35
752	Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. 2015 , 170, 29-39		67
751	Place de la biologie moléculaire pour le diagnostic et le suivi des leucémies aiguës. 2015 , 2015, 51-64		1
750	Place de la cytogénétique dans le diagnostic des leucémies aiguës myéloïdes. 2015 , 2015, 43-49		
749	Ni-Catalyzed C-H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543. 2015 , 80, 6001-11		21
748	Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. 2015 , 70, 34-43		5
747	Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. 2015 , 29, 2113-6		31
746	Toxic encephalopathy after exposure to azacitidine. 2015 , 56, 1538-9		1
745	3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. 2015 , 11, 1675-86		21

744	Mutational profile of childhood myeloproliferative neoplasms. 2015 , 29, 2407-9	18
743	Innate Lymphoid Cells in Cancer. 2015 , 3, 1109-14	26
742	The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. 2015 , 56, 3437-9	19
741	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. 2015 , 5, e333	89
740	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. 2015 , 39, 1443-7	8
739	Novel drug therapies in myeloid leukemia. 2015 , 4, 187-205	12
738	Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. 2015 , 15 Suppl, S85-90	
737	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. 2015 , 90, 1623-38	10
736	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. 2015 , 16, 1691-9	254
735	Pathogenesis of myeloproliferative neoplasms. 2015 , 43, 599-608	72
734	A Ranking Approach for Probe Selection and Classification of Microarray Data with Artificial Neural Networks. 2015 , 22, 953-61	1
733	Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia. 2015 , 34, 55	10
732	Budd-Chiari syndrome: investigation, treatment and outcomes. 2015 , 91, 692-7	27
731	Albumin as a prognostic marker in myelodysplastic syndromes: still relevant after all these years. 2015 , 56, 2491-2	4
730	Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. 2015 , 14, 2364-73	36
729	Up-front allogeneic hematopoietic cell transplantation in acute myeloid leukemia arising from the myelodysplastic syndrome. 2015 , 133, 183-92	3
728	Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms. 2015 , 8, 160-6	4
727	Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. 2015 , 56, 97-102	8

726	REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. 2015 , 168, 796-805	27
725	Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort. 2015 , 169, 584-9	17
724	The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes. 2015 , 37 Suppl 1, 115-21	38
723	Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China. 2015 , 19, 413-21	6
722	Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome. 2015 , 8, 28-33	24
721	Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly. 2015 , 22, 341-7	9
720	Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. 2015 , 39, 957-63	27
719	Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. 2015 , 102, 587-93	22
718	Management of Hematologic Malignancies: Special Considerations in Pregnant Women. 2015 , 75, 1725-38	53
717	A PI3K p110 β /Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. 2015 , 6, 8501	36
716	How we diagnose and treat essential thrombocythaemia. 2015 , 171, 306-21	12
715	Perioperative blood product administration and thromboembolic events in patients with treated polycythemia vera: a case-control study. 2015 , 55, 1090-7	7
714	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. 2015 , 90, 859-63	15
713	TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. 2015 , 171, 91-9	29
712	NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. 2015 , 56, 3222-6	17
711	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. 2015 , 100, 1117-30	79
710	A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. 2015 , 5, e335	67
709	T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. 2015 , 5, e340	44

708	Incidence and Burden of the Myelodysplastic Syndromes. 2015 , 10, 272-81			82
707	Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview. 2015 , 37, 348-53			17
706	Anemia as the Main Manifestation of Myelodysplastic Syndromes. 2015 , 52, 348-56			25
705	The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. 2015 , 15, 1019-36			15
704	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. 2015 , 15, 546-9			15
703	Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML. 2015 , 144, 484-92			11
702	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. 2015 , 525, 543-547			327
701	A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia. 2021 , 105, 106573			1
700	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2021 ,	2.2		14
699	Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms. 2021 , 16, 48-55			1
698	Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. 2021 , 21, 734-740			5
697	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. 2021 , 107, 354-363			0
696	Chronic Myelomonocytic Leukemia Gold Jubilee. 2021 , 2, 403-428			
695	Incidence and outcomes of refractory immune thrombocytopenic purpura in children: a retrospective study in a single institution. 2021 , 11, 14263			3
694	Isolated myeloid sarcoma of lumbar spine without bone marrow involvement: a rare case report and treatment dilemma. 2021 , 5, 27			1
693	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021 , 138, 2337-2346	2.2		4
692	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). 2021 , 39, 3318-3327			7
691	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. 2021 , 39, 558-566			4

690	Current Treatment of Juvenile Myelomonocytic Leukemia. 2021 , 10,	0
689	Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle. 2021 , 26, 245-257	0
688	Guanylate-binding proteins induce apoptosis of leukemia cells by regulating MCL-1 and BAK. 2021 , 10, 54	1
687	Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients. 2021 , 21, e960-e969	1
686	Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. 2021 , 13, 1129-1143	0
685	Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study. 2021 , 78, e743-e748	
684	Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. 2021 , 27, 6095-6105	4
683	A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia. 2021 , 11, 702239	1
682	Unraveling the Connections between Calreticulin and Myeloproliferative Neoplasms via Calcium Signalling.	0
681	Blastic Plasmacytoid Dendritic Cell Neoplasm without Cutaneous Manifestation: A Case Report. 2021 , 22, e932887	
680	Effect Of Genetic Characteristics On Survival In Myelodysplastic Syndrome. 2021 , 0-0	
679	Myeloid Sarcoma Presenting as Obstructive Jaundice. 2021 , 15, 695-702	
678	Alterations of Signaling Pathways in Essential Thrombocythemia with Calreticulin Mutation. 2021 , 13, 6231-6238	2
677	Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. 2021 , 100, 2707-2716	5
676	The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis. 2021 , 5, 3216-3226	5
675	High expression of long noncoding RNA NORAD is associated with poor clinical outcomes in non-M3 acute myeloid leukemia patients. 2021 ,	0
674	TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. 2021 , 43, 917-931	0
673	Pretransplantation Red Blood Cell and Platelet Transfusion Burden in De Novo Myelodysplastic Syndrome Undergoing Allogeneic Transplantation. 2021 , 27, 671-678	1

672	Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. 2021 , 1-9	
671	Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. 2021 , 13, 169	
670	Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. 2021 , 56, 3016-3023	0
669	Programmed necroptosis is upregulated in low-grade myelodysplastic syndromes and may play a role in the pathogenesis. 2021 , 103, 60-72.e5	
668	Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm. 2021 , 36, 1190-1203	2
667	Usefulness of Leucocyte Cell Population Data by Sysmex XN1000 Hematology Analyzer in Rapid Identification of Acute Leukemia. 1	0
666	Chloroma of the Bladder: A Case Report of Leukemia Progression Presenting as Hematuria. 2021 , 14, 1366-1372	0
665	Spatial disparities in the reported incidence and survival of myeloproliferative neoplasms in Australia. 2021 ,	0
664	Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. 2021 , 35, 3339-3351	7
663	Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia. 2021 , 100, e26959	0
662	Comparison of Upfront Transplantation and Pretransplant Cytoablative Therapy for Advanced Myelodysplastic Syndrome. 2021 , 21, 631-640	0
661	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. 2021 , 11, 751668	0
660	Prognosis and Outcome of Fit Patients with Acute Myeloid Leukemia in Kuwait. 2021 , 21, e736-e743	0
659	Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report. 2021 , 1	1
658	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. 2021 , 110, 106715	1
657	Importance of targeted therapies in acute myeloid leukemia. 2021 , 107-133	0
656	Prognostic impact of peripheral blood mRNA expression levels in response to azacitidine in MDS: A single-centre analysis. 2021 , 15, 100231	
655	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. 2021 , 100, 1995-2004	1

654	Special Clinical Scenarios: Extramedullary Disease. 2021 , 275-283	
653	Genomic Landscape and Clonal Evolution of AML. 2021 , 103-118	
652	Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. 2021 , 12, 2975-2981	
651	Increased risk of leukaemia in children with Down syndrome: a somatic evolutionary view. 2021 , 23, e5	1
650	Secondary AML. 2021 , 71-101	
649	Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. 2021 , 21, 59	5
648	Immunophenotypic aberrancy in acute leukemia in a retrospective single institute study.	
647	Molecular Genetics of Myelodysplastic Syndromes.	1
646	Acute myeloid leukemia. 62-125	2
645	Laboratory Diagnosis of Haematological Neoplasms. 395-414	1
644	Acute Myeloid Leukemia. 2014 , 239-255	1
643	Role of Sphingolipids in Hematological Malignancies: Myeloproliferative Disorders. 2015 , 53-79	1
642	Blast Crisis of Chronic Myeloid Leukemia (CML). 2020 , 1135-1145	1
641	Hematological Neoplasms. 2016 , 1493-1510	2
640	Epidemiology of Acute Childhood Leukemia. 2011 , 3-26	1
639	Molecular Biology of Acute Lymphoblastic Leukemia. 2012 , 3-28	1
638	Nuclear phosphoinositides: location, regulation and function. 2012 , 59, 335-61	27
637	Nuclear PI-PLC β and Myelodysplastic syndromes: from bench to clinics. 2012 , 362, 235-45	7

636	Classification of Blood Cancer and Form Associated Gene Networks Using Gene Expression Profiles. 2019 , 95-106	1
635	Acute Myeloid Leukemia. 2011 , 672-697	3
634	Childhood Leukemia. 2014 , 1849-1872.e11	4
633	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. 2020 , 42, 100706	26
632	Genetic polymorphisms and expression of NLRP3 inflammasome-related genes are associated with Philadelphia chromosome-negative myeloproliferative neoplasms. 2020 , 81, 606-613	6
631	World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 [major changes from the 3rd edition, 2001]. 2011 , 57, 66-73	5
630	Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. 2018 , 32, 383-390	105
629	Automatic identification of informative regions with epigenomic changes associated to hematopoiesis.	1
628	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group". 2020 , 105, 335-343	1
627	Fever without a source: evolution of a diagnosis from Kawasaki disease to acute myelogenous leukaemia. 2017 , 2017,	2
626	Cardiac disease in a case of precursor B acute lymphoblastic leukaemia with eosinophilia(ALL/Eo). 2012 , 2012,	4
625	Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. 2020 , 10, e040467	3
624	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. 2018 , 3,	30
623	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. 2017 , 127, 2206-2221	45
622	Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia. 2021 , 17, e517-e525	2
621	Blastic Plasmacytoid Dendritic Cell Neoplasm with Pulmonary Involvement and Atypical Skin Lesion. 2017 , 18, 692-695	8
620	Management of thrombocythemia. 2014 , 3, 227	3
619	Expansion of Primary Human AML by Aryl Hydrocarbon Receptor Antagonism Minimally Affects Leukemic Transcriptional Profiles but Alters Cellular Metabolism. 2016 , 2, 9-16	1

618	Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report. 2020 , 8, 2833-2840	1
617	Effect of <i>Orostachys japonicus</i> on Apoptosis and Autophagy in Human monocytic leukemia Cell line THP-1 via Inhibition of NF- κ B and Phosphorylation of p38 MAPK. 2019 , 40, 35-50	0
616	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. 2016 , 12, e1004890	21
615	Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. 2011 , 6, e26534	13
614	Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder. 2011 , 6, e28350	18
613	Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome. 2012 , 7, e51339	29
612	Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseases. 2013 , 8, e53544	8
611	Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma. 2013 , 8, e56829	15
610	Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemia. 2013 , 8, e76989	25
609	The GIII CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities. 2014 , 9, e88879	10
608	Development and validation of a 3-Plex RT-qPCR assay for the simultaneous detection and quantitation of the three PML-RARa fusion transcripts in acute promyelocytic leukemia. 2015 , 10, e0122530	7
607	Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. 2015 , 10, e0129375	8
606	Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments. 2016 , 11, e0158649	3
605	The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia. 2016 , 11, e0162638	16
604	Myelodysplastic syndrome patients present more severe respiratory muscle impairment and reduced forced vital capacity: Is disordered inflammatory signaling the culprit?. 2017 , 12, e0184079	2
603	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. 2017 , 12, e0184747	9
602	Mixed Phenotype Acute Leukemia with Low Hypodiploidy in a Pediatric Patient. 2015 , 3, 24-28	3
601	Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk. 2021 , 116, 741-747	4

600	Quantitative histological image analyses of reticulin fibers in a myelofibrotic mouse. 2016 , 3,	9
599	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. 2013 , e256-e270	1
598	Transient Abnormal Myelopoiesis: A Varied Spectrum of Clinical Presentation. 2017 , 6, 25-28	2
597	Retrospective Study of High Hemoglobin Levels in 56 Young Adults. 2018 , 7, 43-50	2
596	Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia. 2020 , 9, 13-17	1
595	Acute Undifferentiated Leukemia or Minimally Differentiated Acute Myeloid Leukemia: Further Emphasis on Molecular Analysis in Leukemia Diagnosis. 2016 , 62, 37-41	2
594	Myelodysplastic syndrome with myelofibrosis in a 12-year-old patient [A case report]. 2018 , 26, 95-103	3
593	C/EBP β dysregulation in AML and ALL. 2011 , 16, 93-102	45
592	[Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia]. 2016 , 88, 104-108	1
591	High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome. 2017 , 16, 197-209	11
590	[Activity of matrix metalloproteinases MMP-2 and MMP-9 in bone marrow plasma of patients with acute myeloid leukemia]. 2013 , 59, 578-84	2
589	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. 2016 , 7, 49539-49551	10
588	Nucleophosmin leukemogenic mutant activates Wnt signaling during zebrafish development. 2016 , 7, 55302-55312	11
587	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). 2016 , 7, 63177-63188	13
586	CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. 2013 , 4, 1438-48	18
585	Clonal evolution in therapy-related neoplasms. 2017 , 8, 12031-12040	15
584	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. 2017 , 8, 37866-37874	8
583	Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia. 2017 , 8, 79126-79136	22

- 582 Classification of pediatric acute myeloid leukemia based on miRNA expression profiles. **2017**, 8, 33078-33085 8
- 581 Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. **2017**, 8, 79414-79424 2
- 580 Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. **2017**, 8, 81926-81935 11
- 579 Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. **2017**, 8, 79073-79086 38
- 578 Suppression of miR-708 inhibits the Wnt/ β -catenin signaling pathway by activating DKK3 in adult B-all. **2017**, 8, 64114-64128 14
- 577 XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. **2014**, 5, 4337-46 19
- 576 High bone marrow expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia. **2017**, 8, 91979-91989 9
- 575 Risk stratification in therapy-related myelodysplastic syndromes. **2017**, 8, 80103-80104 4
- 574 The versatile nature of miR-9/9 in human cancer. **2018**, 9, 20838-20854 41
- 573 Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. **2018**, 9, 19342-19355 10
- 572 Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. **2018**, 9, 26724-26736 9
- 571 Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. **2015**, 6, 9612-26 125
- 570 Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. **2015**, 6, 8388-96 52
- 569 Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death. **2015**, 6, 17192-205 25
- 568 Mutations of c-Cbl in myeloid malignancies. **2015**, 6, 10689-96 14
- 567 HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia. **2016**, 7, 3623-34 7
- 566 Targeting SHP2 phosphatase in myeloproliferative neoplasms. **2012**, 3, 1049-51 3
- 565 Novel evidence that pituitary gonadotropins directly stimulate human leukemic cells-studies of myeloid cell lines and primary patient AML and CML cells. **2016**, 7, 3033-46 16

564	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. 2012 , 3, 1588-99	126
563	Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. 2016 , 7, 30084-93	39
562	Crucial factors of the inflammatory microenvironment (IL-1/TNF- α /TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. 2016 , 7, 43974-43988	16
561	Which clinical significance has automatic detection of very low levels of nucleated red blood cells in the peripheral blood?. 2016 , 4, 230	6
560	Implication of microRNAs in the pathogenesis of MDS. 2012 , 18, 3170-9	13
559	MicroRNAs in Myeloid Hematological Malignancies. 2015 , 16, 336-48	5
558	The Evolving AML Genomic Landscape: Therapeutic Implications. 2020 , 20, 532-544	3
557	Role of Unani Medicines in Cancer Control and Management. 2019 , 14, 92-113	6
556	Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. 2016 , 17, 4647-4653	6
555	CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. 2020 , 111, 455-466	3
554	Risk of Acute Lymphoblastic Leukemia: Results of a Case-Control Study. 2019 , 20, 2477-2483	5
553	Association of Multidrug Resistance Gene-1 (MDR1 C1236T) Polymorphism with the Risk of Acute Myeloid Leukemia in a Moroccan Population. 2020 , 21, 1899-1904	1
552	Myelodysplastic syndromes: moving towards personalized management. 2020 , 105, 1765-1779	21
551	Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA. 2020 , 8, 604391	4
550	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. 2020 , 17,	0
549	The role of microRNAs in acute myeloid leukemia. 2010 , 2, 81	3
548	[Autophagy level of bone marrow mononuclear cells in patients with myelodysplastic syndromes]. 2015 , 36, 1016-9	2
547	[EVI1 expression, clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia]. 2016 , 37, 936-941	1

546	Phenotype of mesenchymal stem cells from patients with myelodysplastic syndrome maybe partly modulated by decitabine. 2019 , 18, 4457-4466	3
545	Frequency of hematologic malignancies in the population of Arica, Chile. 2019 , 18, 5637-5643	5
544	Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia. 2015 , 30, 884-90	4
543	Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. 2017 , 32, 890-899	12
542	Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. 2019 , 34, 390-400	11
541	Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. 2018 , 33, 790-797	9
540	Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome. 2020 , 35, 457-464	8
539	Potential of Celosia species in alleviating micronutrient deficiencies and prevention of diet-related chronic diseases: a review. 2019 , 4, 458-484	3
538	Down syndrome and leukemia: insights into leukemogenesis and translational targets. 2015 , 4, 76-92	43
537	Dual transcripts of - & different polymorphisms in chronic myeloid leukaemia patients. 2016 , 143, S136-S141	3
536	Myeloid sarcoma of the periprostatic tissue and prostate: Case report and review of literature. 2016 , 8, 348-54	5
535	Results of treatment of acute myeloid leukemia in central part of Iran. 2013 , 2, 51	6
534	From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia. 2016 , 5, 187	5
533	Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm. 2017 , 6, 75-78	1
532	Indolent Systemic Mastocytosis Manifesting as Protracted Anaphylactic Shock. 2018 , 22, 311-313	3
531	Initial Analysis of Lipid Metabolomic Profile Reveals Differential Expression Features in Myeloid Malignancies. 2015 , 06, 1262-1272	3
530	Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems. 2016 , 33, 119-26	3
529	Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. 2017 , 34, 27-33	8

528	Diagnostic Problems in Chronic Basophilic Leukemia. 2018 , 35, 283-289	1
527	Extracorporeal Life Support in Patients with Hematologic Malignancies: A Single Center Experience. 2016 , 49, 280-6	6
526	Influence of Prognostic Factors on Overall Survival in Myelodysplastic Syndromes. 2014 , 26, 292-6	5
525	The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. 2011 , 33, 176-7	3
524	Philadelphia-negative chronic myeloproliferative neoplasms. 2012 , 34, 140-9	9
523	Laboratory diagnosis of chronic myelomonocytic leukemia and progression to acute leukemia in association with chronic lymphocytic leukemia: morphological features and immunophenotypic profile. 2012 , 34, 242-4	4
522	Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. 2012 , 34, 367-82	6
521	Current Cytogenetic Abnormalities in Acute Myeloid Leukemia.	0
520	Annotation of genes having candidate somatic mutations in acute myeloid leukemia with whole-exome sequencing using concept lattice analysis. 2013 , 11, 38-45	2
519	Multiparameter flow cytometry in the diagnosis and management of acute leukemia. 2011 , 135, 44-54	67
518	Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. 2013 , 68, 339-43	7
517	Oral and pharyngeal cancer among the Arab population in Israel from 1970 to 2006. 2012 , 13, 585-9	10
516	Revisiting use of growth factors in myelodysplastic syndromes. 2012 , 13, 1081-91	10
515	Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia. 2014 , 15, 221-7	15
514	Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review. 2014 , 15, 1603-9	10
513	Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?. 2016 , 17, 923-6	8
512	Pretreatment platelet count predicts survival outcome of patients with non-M3 acute myeloid leukemia. 2017 , 5, e4139	9
511	Extensive Bone Marrow Necrosis and Osteolytic Lesions in a Case of Acute Myeloid Leukemia Transformed from Polycythemia Vera. 2016 , 8, e639	10

510	Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing. 2021 , e1573	
509	Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey. 2021 ,	0
508	The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. 2021 ,	0
507	Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment. 2021 , 57,	1
506	The TRIM proteins in cancer: from expression to emerging regulatory mechanisms. 2021 , 1	0
505	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. 2021 , 22, 1597-1608	17
504	Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. 2021 , 1-9	2
503	Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials. 2021 , 11, 708727	1
502	Recent Advances in the Management of Pediatric Acute Myeloid Leukemia-Report of the Hungarian Pediatric Oncology-Hematology Group. 2021 , 13,	0
501	Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. 2021 , 12, 6060	2
500	Sensitive Oxidation of Sorbitol-Mediated Fe by HO: A Reliable TD-NMR Method for Clinical Blood Glucose Detection. 2021 , 93, 14153-14160	1
499	Advances in acute myeloid leukemia. 2021 , 375, n2026	16
498	Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. 2021 , 10, 7585-7592	2
497	Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. 2021 ,	1
496	Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3 T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients. 2021 , 11, 741341	
495	Diagnosis and Classification of the BCR-ABL1-Negative Myeloproliferative Neoplasms. 2011 , 1-37	
494	Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosis. 2011 , 205-221	
493	Blastic Transformation of Classic Myeloproliferative Neoplasms. 2011 , 169-180	

- 492 Treatment of Acute Myeloid Leukemia. **2011**, 121-160 1
- 491 The Myelodysplastic Overlap Syndromes. **2011**, 159-173
- 490 Hämatologische und immunologische Krankheiten. **2011**, 217-245
- 489 Bone marrow. **2011**, 1927-2012
- 488 Principles of Classification of Myeloid Neoplasms. **2011**, 649-655
- 487 Non-Cytogenetic Markers and their Impact on Prognosis. 56-76
- 486 Myelodysplastic Syndromes. 99-114
- 485 Mixed Phenotype Acute Leukemia. **2011**, 159-165
- 484 The History of the Myelodysplastic Syndromes. **2011**, 1-4 1
- 483 Acute Myeloid Leukemia. 103-126
- 482 Myelodysplastic Syndromes (MDS). **2012**, 149-168
- 481 Use of rHuG-CSF in Myelodysplastic Syndromes. **2012**, 183-193 1
- 480 A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy. **2012**, 203-214
- 479 Critical Issues About the Diagnosis of MPNs: Bone Marrow Histopathology. **2012**, 19-35
- 478 Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms. **2012**, 131-145
- 477 Nontransplant Treatment Options for Myelofibrosis: How to Treat Anemia, Splenomegaly, Constitutional Symptoms, and Extramedullary Disease. **2012**, 177-186
- 476 Krankheiten des Blutes und der blutbildenden Organe. **2012**, 579-605
- 475 Myelodysplasia and Myeloid Proliferations. **2012**, 75-100

474 Acute Leukemia. **2012**, 21-51

473 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61

472 Myeloproliferative and Overlap Myelodysplastic/Myeloproliferative Neoplasms. **2012**, 479-522

471 Myelodysplastic Syndromes. **2012**, 523-546

470 Mastocytosis. **2012**, 588-611

469 Hematopoietic Malignancies. **2012**, 1371-1396

468 Leukocytosis at Diagnosis in Patients with Essential Thrombocythemia Is a Risk Factor for Transformation into Myelofibrosis. **2012**, 02, 46-50

467 Epidemiology and Etiology. **2013**, 9-38

466 Diagnóstico molecular de las neoplasias mieloproliferativas. **2013**, 7-15

465 Hematopoietic and Lymphoid Systems. **2013**, 407-458

464 Pharmacogenomics in Acute Myeloid Leukemia. **2013**, 237-248

1

463 Relative Monocytosis in Patients with Erythrocytosis. **2013**, 03, 21-24

462 A Personalized Molecular Pathogenesis of MDS. **2013**, 97-109

461 Prognostic Models for Patients with Myelodysplastic Syndromes. **2013**, 153-167

460 Tratamiento de la trombocitemia esencial. **2013**, 45-51

459 Is FLT3 Internal Tandem Duplication an Unfavorable Risk Factor for High Risk Children with Acute Myeloid Leukemia? [Polish Experience.

458 CHAPTER 7: The Diagnosis of Myelodysplastic Syndromes. **2013**, 182-200

457 Lenalidomide for patients with red blood cell transfusion-dependent low- or intermediate-1-risk IPSS myelodysplastic syndromes.

456 Chemotherapy-without-Ara-C versus Chemotherapy-with-Ara-C for treatment of newly diagnosed acute promyelocytic leukemia.

455 MicroRNAs in Hematologic Malignancies. **2014**, 67-95

454 Acute Myeloid Leukemia. **2014**, 221-249

453 PTK2 and PTPN11 expression in myelodysplastic syndromes. **2013**, 68, 1371-5

452 Intraocular Manifestations of Hematopoietic Disorders. **2014**, 319-330

451 Akute myeloische Leukämie. **2014**, 1-13

450 WHO Classification of Hematologic Malignancies. **2014**, 219-225.e2

449 Myelodysplastic syndromes etiology and pathophysiology. **2014**, 6-19

448 Contraception for Women with Hematologic Abnormalities. **2014**, 181-204

447 Myelodysplastic Syndromes. **2014**, 1907-1928.e8

446 Myeloproliferative Neoplasms. **2014**, 1929-1943.e4

445 Acute Leukemias in Adults. **2014**, 1890-1906

444 Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia. **2012**, 29-53

443 Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis. **2014**, 15, 6767-72 3

442 Myelodysplastic Syndromes in Older Patients. **2015**, 49-61

441 Myeloproliferative Neoplasms. **2015**, 101-112

440 Frequency of chromosomal abnormalities in Pakistani adults with acute lymphoblastic leukemia. **2014**, 15, 9495-8 4

439 Indications for Hematopoietic Transplantation for AML. **2015**, 777-797

438 Acute Lymphoblastic Leukemia. **2015**, 915-932

437 Second Malignancies Following Treatment for Childhood Cancer. **2015**, 353-367

436 [The specific features of diagnosis of mixed-phenotype acute leukemia: A combination of B-cell antigen expressions according to the results of flow cytometry and morphological markers of myeloid differentiation in blast cells: A clinical case]. **2015**, 87, 97-100 1

435 Frequency and Clinicohematologic Characteristics of MPLW515 Mutations in Patients with Myeloproliferative Neoplasms. **2015**, 5, 1 1

434 Akute myeloische Leukämie (AML) im Kindesalter. **2015**, L11.1-L11.12

433 Second Malignant Neoplasms. **2015**, 209-220

432 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

431 Mucormycosis presenting with dental pain and palatal ulcer in a patient with chronic myelomonocytic leukaemia: case report and literature review. **2015**, 2, 0

430 Milestones in the curability of pediatric cancers. **2015**, 32-40

429 Molecular genetics and Cytogenetics data of 317 patients with de novo acute leukemia. **2015**, 6, 1 1

428 Interferon therapy for myelofibrosis. **2015**, 86-102

427 Myelodysplastic syndromes. 126-152

426 Leukaemia. 427-448

425 Integrative Construction of Gene Signatures Based on Fusion of Expression and Ontology Information. **2016**, 237-249

424 Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases. **2015**, 16, 7875-82 6

423 Therapy-Related Myeloid Neoplasms. **2016**, 5-134-5-137

422 A unique rearrangement of PDGFR β and ETV6 in a patient with acute myeloid leukemia with myelodysplasia-related changes progressed from chronic myelomonocytic leukemia. **2016**, 4, 1 1

421 Serum Levels of Testosterone in Patients with Polycythemia Vera. **2016**, 06, 17-22

- 420 Overview. **2016**, 1501-1505.e3 1
- 419 Acute Myeloid Leukemia. **2016**, 527-559
- 418 Diagnostic Applications of Nuclear Medicine: Leukemias. **2016**, 1-31
- 417 Myelodysplastische Syndrome. **2016**, 1-9
- 416 Overview of Myelodysplastic/Myeloproliferative Neoplasms. **2016**, 5-72-5-73
- 415 Acute Lymphoblastic Leukemia. **2016**, 561-577
- 414 [Diagnosis of latent polycythemia vera: A clinician's opinion]. **2016**, 88, 25-30 1
- 413 Chronic Myeloid Leukemia Relapsing as Isolated Extramedullary Disease Presenting as a Cardiac Mass. **2016**, 90, 159-162
- 412 7. Conjoint deficiency of vitamin C and NQO1 causes cigarette smoke-induced myelodysplastic syndrome. **2016**, 123-140
- 411 Multiplex RT-PCR Assay for Detection of Common Fusion Transcripts in Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Cases. **2016**, 17, 677-84 1
- 410 Les cellules innées lymphoïdes : des nouveaux acteurs de l'immunité **2016**, 200, 561-574
- 409 Increasing the Efficacy of Detecting Residual Cancer Cells Using a Whole-Slide Image Scanning Method and a Computer-Aided Detection Scheme. **2016**, 1,
- 408 Leukemia. **2017**, 987-1005
- 407 Optimal Phlebotomy Interval to Change Hematocrit Levels in Patients with Polycythemia. **2016**, 27, 220-228 0
- 406 Cancer Genetics at a Glance: The Comprehensive Insights. **2017**, 79-389 1
- 405 Blood and Cancer. **2017**, 295-330
- 404 Cord Blood Transplants for Myeloid Malignancies in Children. **2017**, 141-150
- 403 Antileukemic Activity of Sulforaphane. **2017**, 301-317 1

- 402 Chloroma of the testis in a patient with a history of acute myeloid leukemia. **2017**, 22, 83
- 401 Diagnostic Applications of Nuclear Medicine: Leukemias. **2017**, 435-465
- 400 Acute Myeloid Leukemia (AML). **2017**, 89-90
- 399 Acute Myeloid Leukemia. **2017**, 61-85
- 398 A CLINICO-MORPHOLOGIC STUDY OF MYELOPROLIFERATIVE NEOPLASMS. **2017**, 6, 1375-1378
- 397 Leukaemia. 427-448
- 396 Clinico Hematological Profile of Acute Promyelocytic Leukemia. **2017**, 4, ○
- 395 Pathophysiology of Chronic Myelomonocytic Leukemia New Insights from Molecular and Biologic Characterization. **2017**, 3, 1-10
- 394 Molecular Genetic Abnormalities in the Pathogenesis of Hematologic Malignancies and Corresponding Changes in Cell Signaling Systems. **2017**, 10, 235-249 ○
- 393 Cytogenetic and Molecular Genetic Prognostic Factors of Acute Myeloid Leukemia. **2017**, 10, 227-234
- 392 Anticancer therapy - related acute myeloid leukemias. **2017**, 11, 115-120
- 391 Detection of human disease conditions by single-cell morpho-rheological phenotyping of whole blood.
- 390 . **2017**, 22, 45-46
- 389 Existing and Emerging Molecular Technologies in Myeloid Neoplasms. **2018**, 369-412
- 388 Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Therapy-Related Myeloid Neoplasms, and Acute Myeloid Leukemia, Not Otherwise Specified. **2018**, 47-82
- 387 The Myelodysplastic Syndromes. **2018**, 483-508
- 386 Radiation Therapy in Precursor T-Lymphoblastic Lymphoma/Leukemia. **2018**, 1-9
- 385 Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemia.

384 Impact of CNA on AML prognosis. **2018**, 9, 12540-12541

383 Mastocytosis. **2018**, 617-641.e4

382 Overview of Myeloproliferative Neoplasms. **2018**, 458-461

381 Acute Myeloid Leukemia Without Maturation (AML, NOS). **2018**, 676-677

380 Overview of Myelodysplastic/Myeloproliferative Neoplasms. **2018**, 542-545

379 Acute Myelomonocytic Leukemia (AML, NOS). **2018**, 680-681

378 Overview and Classification of Myelodysplastic Syndromes. **2018**, 566-575

377 Pathology of Intestinal Transplantation. **2018**, 1-24

376 Interface Between Oral and Systemic Disease. **2018**, 1-70

1

375 Therapy-Related Myeloid Neoplasms. **2018**, 668-673

374 Acute Myeloid Leukemia With Myelodysplasia-Related Changes. **2018**, 662-667

373 Genetic Polymorphisms of coagulation factors and platelet glycoproteins in patients with chronic myeloproliferative neoplasms. **2018**, 7, 20

372 Acute Myeloid Leukemia With Maturation (AML, NOS). **2018**, 678-679

371 Morphology and Flow Cytometry. **2018**, 3-13

370 Overview and Classification of Myeloid Neoplasms. **2018**, 450-455

369 Acute Undifferentiated Leukemia. **2018**, 712-715

368 Acute Myeloid Leukemia With Minimal Differentiation (AML, NOS). **2018**, 674-675

367 Assessment of risk factors affecting thrombosis in patients with Essential Thrombocytosis in our clinic.

0

- 366 Pediatric myelodysplastic syndrome. **2018**, 5, 23-35 2
- 365 Epidemiological and survival data of adult lymphoma patients: single centre experience. **2018**, 10, 240-246
- 364 Clinical and pathological features DNMT3A, FLT3, KIT, NPM1, NRAS, TP53 and WT1 genes mutations detection in acute myeloid leukemia patients aged 15-55 years old. **2018**, XIII,
- 363 Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia. **2019**, 56, 167-172
- 362 Myelodysplastic Syndromes. **2019**, 913-942
- 361 De novo acute myeloid leukemia with t(8;21)(q22;q22) and monosomy 7. **2019**, 10, 99
- 360 Myelodysplastic Syndrome. **2019**, 1-21
- 359 Pathology of Intestinal Transplantation. **2019**, 319-342
- 358 Intraocular Manifestations of Hematopoietic Disorders. **2019**, 365-377 0
- 357 Quantitative Assay of Mutated Nucleophosmin in Acute Myeloid Leukemia. **2019**, 8, 111-120
- 356 Acute Lymphoblastic Leukemia. **2019**, 893-911
- 355 Blood cell activation as an indicator of prothrombogenesis in polycythemia vera: Case control study. **2019**, 8, 74
- 354 Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation. **2019**, 20, 2426-2432 6
- 353 [Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome]. **2019**, 91, 93-99 0
- 352 Postępowanie w chłoniakach z obwodowych limfocytów T i NK. **2019**, 50, 57-64
- 351 The role of neuronal apoptosis inhibitory protein (NAIP) in acute myeloid leukemia patients. **2019**, 50, 74-80
- 350 Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases. **2019**, 12, 398-405
- 349 Prognosis and outcome of patients with acute myeloid leukemia based on mutation with or without additional abnormal cytogenetics. **2019**, 18, 6766-6774 6

- 348 Evaluation of cellular and humoral indicators immunity in the treatment of various types of sepsis in immunocompromised hemoblastosis patients. **2019**, 21, 43-47
- 347 Mutation lanscape of acute myeloid leukemia in elderly patients. **2019**, XIV,
- 346 Molecular Detection of Fusion Oncogenes in Zambian Patients with Acute Lymphoblastic Leukemia. **2020**, 10, 234-239
- 345 Integrated decoding hematopoiesis and leukemogenesis at single-cell resolution and its clinical implication. ○
- 344 Machine learning to predict 5-year survival among pediatric Acute Myeloid Leukemia patients and development of OSPAM-C online survival prediction tool. ○
- 343 Comprehensive analysis on phenotype and genetic basis of Chinese Fanconi anemia patients: dismal outcomes call for nationwide studies.
- 342 Primary Myeloid Sarcoma of the Ileum and Mesentery Causing Small Bowel Obstruction: Case Report and Literature Review. **2020**, 19, 55-61
- 341 Comunicaõ entre sistemas de informaõ mēdicos. 18, e020015
- 340 Environmental and occupational determinants of myelodysplastic syndrome: A case-control study from Pakistan. **2021**, e1580
- 339 Mouse Models of CMML. **2021**, 22, ○
- 338 Myelodysplastic Syndrome. **2020**, 479-499
- 337 Comprehensive analysis on phenotype and genetic basis of Chinese Fanconi anemia patients: dismal outcomes call for nationwide studies.
- 336 MDS Mimics Including CHIP, ICUS, and CCUS. **2020**, 91-105
- 335 Epidemiology, Etiology, and Clinical Presentation of Myelodysplastic Syndromes. **2020**, 3-17
- 334 Syndromes myēdysplasiques et leucēmies aiguē. **2020**, 270-278.e3
- 333 Accurate Recognition of Leukemia Sub-types by Utilizing a Transfer Learned Deep Convolutional Neural Network. **2020**,
- 332 A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm. **2020**, 7, 57-62
- 331 Role of CD19 and specific KIT-D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities. **2021**, 10, 1091-1102 3

- 330 Automatic Myelofibrosis Grading from Silver-Stained Images. **2021**, 195-205
- 329 Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. **2021**, 365, 1-69 2
- 328 Role of ancillary techniques in diagnosis of challenging common hematological malignancies. **2020**, 22, 57
- 327 Acute Leukemia of Myeloid, Lymphoid, and Ambiguous Lineage and Related Malignancies. **2020**, 383-533 1
- 326 Early Response and Long-Term Outcomes of Ruxolitinib Therapy in Myelofibrosis: Multicenter Retrospective Study in 10 Centers of the Russian Federation. **2020**, 13, 335-345 1
- 325 Myelodysplastic Syndromes. **2020**, 531-557
- 324 Myelodysplastic/Myeloproliferative Neoplasms. **2020**, 559-594
- 323 Incidence in Ph-Negative Myeloproliferative Neoplasms in Armenia from 2005 to 2019. **2020**, 10, 355-368
- 322 The Application of Next-generation Sequencing Tumor Molecular Profiling in the Diagnosis and Management of a Case of Acute Myelogenous Leukemia With MLL-PTD in a Pediatric Heart Transplant Recipient. **2021**, 43, e246-e249 1
- 321 Comprehensive analysis on phenotype and genetic basis of Chinese Fanconi anemia patients: dismal outcomes call for nationwide studies.
- 320 Eryptosis in polycythemia vera and essential thrombocythemia*. **2020**, 74, 69-76 0
- 319 Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. **2021**, 9, 1
- 318 Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. **2021**, 1 0
- 317 ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. **2021**, 0
- 316 Demethylation and upregulation of an oncogene post hypomethylating treatment. 1
- 315 Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients. **2020**, 14, 188-199 2
- 314 Contraception for Women with Hematologic Abnormalities. **2014**, 181-204 0
- 313 Transfusion in Pregnant Patients Receiving Treatment for Leukemia. **2021**, 121-137

312	BCR-ABL negatif kronik myeloproliferatif hastalıkların tanınmadaki genetik analizleri ve bunların klinik etkileri. 2020 , 45, 933-939	
311	Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. 2021 , 106, 3162-3169	0
310	Blood cell counting in neonates: a comparison between a low volume micromethod and the standard laboratory method. 2011 , 9, 400-6	8
309	Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. 2011 , 66, 793-9	3
308	Rational therapeutic options for patients with myeloproliferative neoplasms. 2011 , 122, 11-26	
307	Systemic vasculitis with prolonged pyrexia, recurrent facial urticaria, skin nodules, pleural effusions and venous thrombosis: an unusual presentation of an uncommon disease. 2011 , 9, Doc27	1
306	A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. 2011 , 1, 160-6	17
305	Leukemia cutis presenting clinically as disseminated herpes zoster in a patient with unrecognized acute promyelocytic leukemia. 2012 , 5, 40-3	1
304	Quality of life and physicians' perception in myelodysplastic syndromes. 2012 , 2, 136-47	34
303	Myelodysplastic syndromes in children: where are we today?. 2012 , 12, 216-20	7
302	Emerging therapeutic options for myelofibrosis: a Canadian perspective. 2012 , 2, 170-86	3
301	Genetic technologies in cancer investigation - applications in aggressive lymphoid malignancies. 2012 , 7, 75-9	
300	Value of multifaced approach diagnosis and classification of acute leukemias. 2012 , 7, 254-60	4
299	Cytogenetic Profile of de novo Acute Myeloid Leukemia Patients in Malaysia. 2013 , 9, 26-32	11
298	Chemotherapy causes cancer! A case report of therapy related acute myeloid leukaemia in early stage breast cancer. 2013 , 82, 97-9	2
297	Acute myeloid leukemia with adverse cytogenetic risk. 2012 , 26, 714, 723	1
296	Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?. 2013 , 8, 370-6	
295	Hyperexpression of NOTCH-1 is found in immature acute myeloid leukemia. 2014 , 7, 882-9	8

294	Indolent systemic mastocytosis in a patient with ileocolitis. 2014 , 27, 270-272	1
293	A case of blastic plasmacytoid dendritic cell neoplasm with ecchymotic lesions on the whole body. 2014 , 7, 4391-9	6
292	The role of ATP-binding cassette transporter A2 in childhood acute lymphoblastic leukemia multidrug resistance. 2014 , 4, 118-26	7
291	Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia. 2015 , 8, 5336-44	7
290	The Newly Identified T Helper 22 Cells Lodge in Leukemia. 2015 , 9, 143-54	3
289	Down-regulation of TET2 in CD3+ and CD34+ cells of myelodysplastic syndromes and enhances CD34+ cells proliferation. 2015 , 8, 10840-6	1
288	A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. 2015 , 5, 86-90	1
287	Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran. 2016 , 18, 37-45	2
286	Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. 2016 , 13, 41-54	6
285	Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling. 2016 , 8, 3169-78	29
284	Diagnosis and Classification of Acute Leukemia in Bone Marrow Trepine Biopsies, Utility of a Selected Panel of Minimal Immunohistochemical Markers. 2016 , 10, 138-46	3
283	Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes. 2013 , 23, 109-16	1
282	Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors. 2015 , 6, 532-50	
281	A Case Report of Concurrent IDH1 and NPM1 Mutations in a Novel t(X;2)(q28;p22) Translocation in Acute Myeloid Leukaemia without Maturation (AML-M1). 2015 , 22, 93-97	
280	Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups. 2016 , 17, 5251-5256	4
279	Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia. 2017 , 18, 413-420	1
278	Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. 2016 , 30, 330, 333	
277	Haematological profile of patients with mixed-phenotype acute leukaemia from a tertiary care centre of north India. 2017 , 145, 215-221	1

276	Gene variants of and and the risk of childhood acute lymphoblastic leukaemia; outcome of a case control study from Kashmir, India. 2017 , 6, 77-84	4
275	Characteristics of De Novo Acute Myeloid Leukemia Patients in Palestine: Experience of An-Najah National University Hospital. 2017 , 18, 2459-2464	3
274	A New Indole Derivative Decreased SALL4 Gene Expression in Acute Promyelocytic Leukemia Cell Line (NB4). 2018 , 22, 99-106	11
273	Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes. 2017 , 8, 29-39	5
272	The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome. 2018 , 19, 1825-1831	1
271	Distribution of Chromosomal Abnormalities Commonly Observed in Adult Acute Myeloid Leukemia in Pakistan as Predictors of Prognosis. 2018 , 19, 1903-1906	1
270	The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera. 2018 , 9, 56-66	
269	Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. 2018 , 8, 29-56	19
268	Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. 2018 , 16, 56-66	8
267	A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center. 2019 , 11, 4533-4541	1
266	Rearrangement of PDGFR β gene in a patient with Ph-negative chronic myeloid leukemia t(5;12)(q33;p13) in imatinib mesylate treatment-free remission: a case report. 2019 , 12, 2284-2287	
265	Incidence of upper digestive tract inflammation in children with acute lymphoblastic leukemia at diagnosis. 2018 , 11, 3671-3677	2
264	[Analysis of treatment response and prognostic factors of T-LBL patients treated with pediatric-like ALL therapy following HSCT]. 2020 , 41, 387-393	
263	[Autologous versus unrelated donor stem cell transplantation for adults with primary acute myeloid leukemia in first remission]. 2020 , 41, 365-372	1
262	[Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts]. 2020 , 41, 379-386	1
261	[The clinical feature and outcomes of severe aplastic anemia patients suffered from bacteremia following antithymocyte globulin]. 2016 , 37, 807-812	
260	[Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients]. 2017 , 38, 1017-1023	
259	[Intermediate-high dose cytarabine consolidation therapy in younger adults with acute myeloid leukemia and favorable-intermediate cytogenetic risk: a retrospective study of 124 patients in a single Chinese hospital]. 2019 , 40, 429-431	1

- 258 [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma]. **2018**, 39, 739-744 1
- 257 [Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm]. **2016**, 37, 75-8 0
- 256 [Childhood B-cell acute lymphoblastic leukemia of nonL3 morphology with mature phenotype and MLL-AF9 gene fusion: a case report and literatures review]. **2018**, 39, 947-949 1
- 255 [HLA-10/10 matched unrelated donor versus sibling donor hematopoietic stem cell transplantation for adult acute myeloid leukemia]. **2019**, 40, 460-466
- 254 [Study of iron overload assessment by T2* magnetic resonance imaging in patients with myelodysplastic syndromes]. **2019**, 40, 222-226
- 253 [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial]. **2015**, 36, 547-52
- 252 [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old]. **2019**, 40, 625-632 2
- 251 [Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms]. **2016**, 37, 221-6 0
- 250 [Concurrence of e18a2 and e19a2 in Ph (+) chronic myelogenous leukemia: a case report and literature review]. **2017**, 38, 799-802
- 249 [U2AF1 mutations in 349 patients with myelodysplastic syndrome]. **2017**, 38, 68-70 0
- 248 [Acute myeloid leukemia with t (8;21) (q22;q22) and secondary t (9;22) (q34;q11) : one case report and literatures review]. **2017**, 38, 71-72
- 247 [Frequency and clinical features of ASXL2 gene mutation in acute myeloid leukemia patients with AML1- ETO fusion gene positive]. **2016**, 37, 676-81
- 246 [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia]. **2016**, 37, 682-7 0
- 245 [The usage of comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a multicenter, prospective study]. **2019**, 40, 35-39 0
- 244 [The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts]. **2017**, 38, 876-882 0
- 243 [Gene mutation spectrum and clinical characteristics analysis of 178 patients with essential thrombocytosis]. **2019**, 40, 837-842
- 242 [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis]. **2016**, 37, 576-80 0
- 241 [Clinical characteristics of clonal evolution after immunosuppressive therapy in children with severe/very severe aplastic anemia]. **2017**, 19, 27-33 1

- 240 [Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes]. **2019**, 21, 24-28
- 239 Simplified flow cytometry scoring for diagnosis and prognosis of myelodysplastic symptom. **2020**, 12, 7449-7458 0
- 238 Fatal hyperleukocytic T lymphoblastic lymphoma/leukemia complicated with multi-gene fusion and mutation: clinical revelation and perception. **2020**, 10, 440-446
- 237 The prognostic factors and efficacy of induction chemotherapy in elderly patients with acute myeloid leukemia. **2020**, 10, 320-329
- 236 [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia]. **2021**, 42, 39-44
- 235 [Clinical features and prognosis of childhood acute myeloid leukemia with myelodysplasia-related changes]. **2021**, 23, 271-278
- 234 Telomerase Dysfunction in the Tumorigenesis of Genetic Disorders. **2021**, 10, 56-68 2
- 233 [Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma]. **2021**, 42, 415-419
- 232 [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia]. **2021**, 42, 646-653
- 231 Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report. **2021**, 112, 106758 1
- 230 Atypical Chronic Myelogenous Leukemia, Negative: Diagnostic Criteria and Treatment Approaches. **2021**, 11, 722507 0
- 229 Expression characteristic of and in acute myeloid leukemia. **2021**, 0
- 228 From bulk, single-cell to spatial RNA sequencing. **2021**, 13, 36 8
- 227 Molecular Pathogenesis of -Negative Atypical Chronic Myeloid Leukemia. **2021**, 11, 756348 0
- 226 Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. **2021**, 115, 198 2
- 225 Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival. **2021**, 48, 15-22
- 224 Identification of two downregulated circRNAs in patients with acute B-lymphocytic leukemia.. **2022**, 23, 40
- 223 Lymphoma recognition based on CNN models. **2021**,

222	Understanding mixed phenotypic acute leukemia: A conundrum of six cases with review of literature. 2021 , 10, 127	
221	Battle of the Clones: Somatic Genetic Rescue of Pediatric Patients With MDS Teaches Us About MDS Biology in 2021 and a Platform for the Future. 2022 , 19,	
220	Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.. 2022 , 20, 29	4
219	Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome.. 2022 , 17, e0262484	1
218	Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.. 2022 , 76, 102090	0
217	Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.. 2022 , 42, 299-305	0
216	Mastocytosis.	
215	Precursor Lymphoid Neoplasms. 2020 , 231-244	
214	Unifying heterogeneous expression data to predict targets for CAR-T cell therapy. 2021 , 10, 2000109	0
213	Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia.. 2021 , 10,	
212	Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).. 2022 , 1-8	1
211	Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.. 2022 , 1-8	
210	B/T mixed phenotype acute leukemia with high hyperdiploidy and lineage switch to B-cell acute leukemia.. 2022 , 17, 100289	2
209	Circular RNA circ_0040823 inhibits the proliferation of acute myeloid leukemia cells and induces apoptosis by regulating miR-516b/PTEN.. 2021 , e3404	2
208	Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis-a case-control study.. 2022 , 24, 5	0
207	Small Non-Coding RNAs in Leukemia.. 2022 , 14,	0
206	RECENT ADVANCES IN T-CELL LYMPHOID NEOPLASMS. 2021 ,	0
205	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. 2022 , 12, 26	1

204	The FLT3 internal tandem duplication mutation at disease diagnosis is a negative prognostic factor in myelodysplastic syndrome patients.. 2022 , 113, 106790	
203	The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis.. 2022 , 1-9	2
202	Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network.. 2022 , 14,	0
201	Historical expectations with DNMT1 monotherapy in MDS: When is combination therapy truly 'promising'?. 2022 ,	0
200	Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. 2021 , 11, 472-497	0
199	Early mortality and overall survival in acute promyelocytic leukemia ▯ single-center experience. 2022 , 67, 55-66	
198	Low-Dose DOACs in Very High-Risk MPNs: Less Bleeding But More Arterial Thrombotic Events.	
197	The Dynamics of the Labelling Game: An Essay On FLT3 Mutated Acute Myeloid Leukaemia. 2022 , 121-132	
196	The Historical Relationship Between Meis1 and Leukemia.. 2022 , 1	
195	A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.. 2022 , 1	0
194	Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. 2022 , 14, e2022025	0
193	Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT.. 2022 ,	0
192	Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution.. 2022 , 50, 3000605221078466	0
191	Concurrent ankylosing spondylitis and myelodysplastic syndrome: A case report.. 2022 , 10, 1929-1936	
190	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey.. 2022 , 12, 828072	
189	Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.. 2022 ,	3
188	Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.. 2022 ,	2
187	Multistep pathogenesis of chronic myelomonocytic leukemia in patients.. 2022 ,	0

186 Acute Myeloid Leukemia. **2022**, 557-569

185 Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India.. **2022**, 1

1

184 Methylation of SPRED1: A New Target in Acute Myeloid Leukemia.. **2022**, 12, 854192

183 Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.. **2022**, 23,

1

182 Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.. **2022**, 1

0

181 Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.. **2022**,

0

180 CCL2 rs1024611 Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms.. **2022**, 13,

179 Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia.. **2022**, 14, e23618

0

178 Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phase.. **2022**,

1

177 Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study.. **2022**, 12, 5489

2

176 Characterization of Extramedullary Disease in B-ALL and Response to CAR T-cell Therapy.. **2021**,

3

175 vHTS, 3-D Pharmacophore, QSAR and Molecular docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain. **2021**,

174 Diagnostic and Prognostic Power of Active DNA Demethylation Pathway Intermediates in Acute Myelogenous Leukemia and Myelodysplastic Syndromes.. **2022**, 11,

0

173 Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma.. **2022**, 1-9

172 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms.. **2022**,

1

171 Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.. **2022**,

0

170 Myelofibrosis: genetic characteristics and the emerging therapeutic landscape.. **2021**,

3

169 MLL-SEPT5 Fusion Transcript in Myelodysplastic Syndrome Patient With t(11;22)(q23;q11).. **2021**, 8, 783229

168 Deep Learning Application in Leukemia Diagnosis. 1-11

167 Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. 1

166 Metabolic Reprogramming and Cell Adhesion in Acute Leukemia Adaptation to the CNS Niche.. **2021**, 9, 767510

o

165 Global Assessment of IRF8 as a Novel Cancer Biomarker.

164 Survival benefit of pediatric-based regimen for adults with acute lymphoblastic leukemia: A single-center retrospective cohort.. **2021**,

o

163 The association of complex genetic background with the prognosis of acute leukemia with ambiguous lineage.. **2021**, 11, 24290

162 Bone marrow. 813-942

161 Myeloproliferative neoplasms. 141-154

160 Data_Sheet_1.docx. **2018**,

159 Data_Sheet_1.pdf. **2019**,

158 table_1.xlsx. **2018**,

157 Table_1.docx. **2020**,

156 Table_2.XLSX. **2020**,

155 Data_Sheet_1.pdf. **2020**,

154 Image_1.TIF. **2019**,

153 Table_1.DOCX. **2019**,

152 Table_2.DOCX. **2019**,

151 Table_3.DOCX. **2019**,

150 Table_4.DOCX. 2019,

149	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.. 2022, 215691	0
148	Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myelodysplasies (GFM).. 2022,	0
147	[Clinical outcomes of 31 patients with acute leukemia receiveing modified conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation]. 2021, 42, 763-767	
146	[Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis]. 2021, 42, 814-822	
145	Diagnostic Applications of Nuclear Medicine: Leukemias. 2022, 1-39	
144	Does Waldenstrom's macroglobulinemia also cause bone destruction? A rare case report.. 2022, 50, 3000605221096161	
143	[Radiotherapy for the treatment of leukemia].. 2022, 1-7	0
142	Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes.. 2022, 6, e0713	0
141	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.. 2022,	2
140	Of drills and bones: Giovanni Ghedini and the origin of bone marrow biopsy.. 2022,	
139	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.. 2022, 14,	0
138	Hemorrhages in polycythemia vera and essential thrombocythemia: epidemiology, description, and risk factors, learnings from a large cohort.. 2022,	0
137	Case Report: Juvenile Myelomonocytic Leukemia Underlying Ornithine Transcarbamylase Deficiency Safely Treated Using Hematopoietic Stem Cell Transplantation. 2022, 10,	0
136	Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia .. 2022,	2
135	The Paradox of Myeloid Leukemia Associated with Down Syndrome.. 2022, 115046	1
134	Various types of electrochemical biosensors for leukemia detection and therapeutic approaches.. 2022, 114736	7
133	Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.	0

132	Enhancement of the International prognostic index with β_2 -microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. 2022 , 22,		0
131	Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. 2022 , 27, 620-628		
130	Serum Metabolomics Coupling With Clinical Laboratory Indicators Reveal Taxonomic Features of Leukemia. 2022 , 13,		
129	Pediatric acute myeloid leukemia patients with i(17)(q10) mimicking acute promyelocytic leukemia: Two case reports. 2022 , 10, 5446-5455		
128	CPX-351 yields similar response and survival outcome in younger and older patients with secondary acute myeloid leukemia. 2022 ,		0
127	Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. 2022 ,		0
126	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> ,	2.2	1
125	Comprehensive Analysis and Summary of the Value of Immunophenotypes of Mature NK Cell Tumors for Differential Diagnosis, Treatment, and Prognosis. 13,		0
124	Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms. 2022 , 216, 25-34		1
123	A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. 28,		1
122	Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis. <i>Blood</i> ,	2.2	0
121	Incidence, Time Trends and Geographical Distribution of Leukemia and Multiple Myeloma in Golestan Province, Northern Iran, 2004-2017. 2022 , 25, 360-365		
120	International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. <i>Blood</i> ,	2.2	50
119	Myelodysplastic Syndrome: Diagnosis and Screening. 2022 , 12, 1581		
118	Vitamin D Derivatives in Acute Myeloid Leukemia: The Matter of Selecting the Right Targets. 2022 , 14, 2851		2
117	Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study. 12,		
116	Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process. 2022 , 12, 1658		0
115	Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.		

- 114 Amplified EPOR/JAK2 genes define a unique subtype of acute erythroid leukemia. 1
- 113 Real world study of children and young adults with myeloproliferative neoplasms identifying risks and unmet needs. 0
- 112 Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?. 2022, Myeloma and Leukemia. 2023, 503-528
- 111 Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia. 2022, 14, 265-269
- 110 Novel Aspects of Leukemia Pharmacogenomics. 1
- 109 Unified classification and risk-stratification in Acute Myeloid Leukemia. 2022, 13, 4
- 108 A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia. 2022, 11, 4663 0
- 107 Single cell genomics in AML: extending the frontiers of AML research. 1
- 106 Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts. 0
- 105 The risk and prognostic influence of caspase 9 promotor polymorphisms in Egyptian patients with acute myeloid leukemia.
- 104 Netrin-1 induces the anti-apoptotic and pro-survival effects of B-ALL cells through the Unc5b-MAPK axis. 2022, 20, 1
- 103 Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. 3
- 102 Secondary Acute Myeloid Leukemia: Pathogenesis and Treatment.
- 101 Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. 1
- 100 Leukemias, Lymphomas, and Plasma Cell Disorders. 2023, 237-300
- 99 Genome-Based Medicine for Acute Myeloid Leukemia: Study and Targeting of Molecular Alterations and Use of Minimal Residual Disease as a Biomarker. 2022, 3, 543-568 0
- 98 Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia. 2022, 122, 106954 0
- 97

96	MORPHOLOGICAL FEATURES OF BONE MARROW IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (literature review). 2012 , 14-18	0
95	Diagnostic Applications of Nuclear Medicine: Leukemias. 2022 , 529-567	0
94	Myelodysplastic Syndrome: A Real-World Experience from a Developing Country.	0
93	Clinical and Cytogenetic Characteristics of Children With Leukemia 20-Year Retrospective Study. Publish Ahead of Print,	0
92	SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome. 2022 ,	1
91	Strahlentherapeutische Behandlung von Leukämien. 2022 , 17, 478-484	0
90	Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis. 2022 , 13,	0
89	Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder. 13,	0
88	Overview of Molecular Quantification of the BCR-ABL Oncogene in CML Patients. 2022 , 19, 693-698	0
87	Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.	1
86	Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 2022 , 20, 1033-1062	4
85	Diagnostic challenges in acute monoblastic/monocytic leukemia in children. 10,	1
84	Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia. 2022 , 8, e10610	0
83	Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes. 2022 , 29, 6933-6946	0
82	Allogeneic haematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukaemia: A single-centre experience. 2022 ,	0
81	The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Myeloproliferative Neoplasms.	2
80	Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.	0
79	Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. 2022 , 123, 106962	0

- 78 Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications. ○
- 77 Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center. Volume 15, 7843-7854 ○
- 76 DNA ligase IV deficiency with elevated serum IgG levels suspected to have myelodysplastic syndrome: a case report. **2022**, 22, ○
- 75 Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome. **2022**, 12, ○
- 74 Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial. ○
- 73 Myelodysplastic Syndromes. 1-20 ○
- 72 Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia. ○
- 71 Significance of reduced renal function in patients with chronic myelomonocytic leukemia. ○
- 70 Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry. **2022**, ○
- 69 Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment. **2022**, 156, 113905 ○
- 68 Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia. ○
- 67 Somatic mutations of activating signalling, transcription factor, and tumour suppressor are a precondition for leukaemia transformation in myelodysplastic syndromes. ○
- 66 The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia. **2022**, 1-14 ○
- 65 Myelodysplastic syndromes. **2022**, 8, ○
- 64 Genetic association of TP53 Pro72Arg polymorphism (rs1042522) in Leukemia: An updated meta-analysis of 10 case-control studies. **2022**, 201130 ○
- 63 Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients. **2022**, 6, e792 ○
- 62 The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance. ○
- 61 Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia. ○

60	Significance of C-reactive protein in patients with chronic myelomonocytic leukemia.	0
59	Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia.	0
58	Leucemie mieloidi acute. 2022 , 24, 1-11	0
57	Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.	1
56	All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RAR α Nrf2 complex.	0
55	Single cell guided deconvolution of bulk transcriptomics recapitulates differentiation stages of acute myeloid leukemia and predicts drug response.	0
54	Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience. 13,	0
53	Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. PHARMREV-AR-2022-000612	0
52	Monocytosis in primary care and risk of haematological malignancies.	0
51	Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.	0
50	A Focused Review of Ras Guanine Nucleotide-Releasing Protein 1 in Immune Cells and Cancer. 2023 , 24, 1652	0
49	Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF).	0
48	Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.	0
47	Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL. 2023 , 125, 107018	1
46	The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. 1-11	0
45	Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification.	0
44	Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. 1-12	0
43	Molecular Diagnostics. 2019 , 226-248	0

- 42 Genomics and Diagnostics in Acute Myeloid Leukaemia. **2019**, 161-185 ○
- 41 Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation. ○
- 40 Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review. **2023**, 13, 377 ○
- 39 Recognizing Minor Leukemic Populations with Monocytic Features in Mixed-Phenotype Acute Leukemia by Flow Cell Sorting Followed by Cytogenetic and Molecular Studies: Report of Five Exemplary Cases. **2023**, 24, 5260 ○
- 38 Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores. ○
- 37 Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database. ○
- 36 10-year nationwide trends in incidence, treatment patterns, and mortality of patients with myelodysplastic syndromes in Denmark. **2023**, 128, 107056 ○
- 35 Persistent decreased bone marrow CD3 + CD56 + T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes. **2023**, 110, 575-577 ○
- 34 Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia. 14, ○
- 33 Chronic myeloid leukemia following low dose radioactive iodine (I131) for treatment of papillary thyroid cancer. **2022**, 3, e0237 ○
- 32 Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia. **2023**, 14, 396 ○
- 31 Clinical Features and Genomic Landscape of Myeloproliferative Neoplasm (MPN) Patients with Autoimmune and Inflammatory Diseases (AID). ○
- 30 Advancing Our Clinical Perspectives in Haematology: What Is Your Approach?. 2-9 ○
- 29 Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. **2023**, 19, e559-e569 ○
- 28 Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review. **2023**, 102, e32904 ○
- 27 Blastic Plasmacytoid Dendritic Cell Neoplasm Mimicking Erythema Nodosum: A Case Report. **2023**, 2, ○
- 26 Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. **2023**, 15, 1344 ○
- 25 Prognostication refinement in NPM1 -mutated acute myeloid leukemia stratified by FLT3 -ITD status with different induction doses of cytarabine. ○

24	Albumin-to-Fibrinogen Ratio is an Independent Prognostic Parameter in De Novo non-M3 acute myeloid leukemia.	0
23	Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.	0
22	Flow cytometry in acute leukemia diagnostics. Guidelines of Russian-Belarusian multicenter group for pediatric leukemia studies. 2023 , 22, 165-177	1
21	Management of Newly Diagnosed Acute Myeloid Leukemia in Older Adults.	0
20	The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms. 2023 , 24, 4860	0
19	Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy. 2023 , 19, 100367	0
18	Features of acute megakaryoblastic leukemia diagnosis in a child with Down syndrome. 2023 , 18, 31-38	0
17	Unraveling the connection between calreticulin and myeloproliferative neoplasms via calcium signaling.	0
16	Spondyloarthritis and nonbacterial thrombotic endocarditis as paraneoplastic manifestations in treatment-naïve Burkitt lymphoma.	0
15	Inhibition of Integrin $\alpha 5$ -FAK-MAPK signaling constrains the invasion of T-ALL cells. 2023 , 17, 1-14	0
14	Identifying prognostic gene panels in acute myeloid leukemia. 2023 , 16, 277-287	0
13	Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients.	0
12	Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG. 2023 , 28,	0
11	Loss of IRF8 inhibits the growth of acute myeloid leukemia cells. 2023 , 102, 1063-1072	0
10	Prediction model for drug response of acute myeloid leukemia patients. 2023 , 7,	0
9	Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study. 2023 , 102, 1099-1109	0
8	JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.	0
7	What's New in the Classification, Diagnosis and Therapy of Myeloid Leukemias. 2023 , 4, 112-134	0

- 6 Diagnóstico e manejo da leucemia linfoblástica aguda (LLA): uma revisão literária. **2021**, 2, 45-50
- 5 Place des outils moléculaires dans les leucémies aiguës myéloïdes en 2023. **2023**, 2023, 52-63
- 4 Actualité des classifications des leucémies aiguës myéloïdes. **2023**, 2023, 22-33
- 3 Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia.
- 2 Effect of hypoxia on HIF-1 α and NOS3 expressions in CD34+ cells of JAK2V617F-positive myeloproliferative neoplasms. **2023**, 68, 169-175
- 1 Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connecticut Myeloid Disease Registry: Potential Barriers to Care. **2023**,